Anti-diabetes and neuroprotection potential and primary safety studies of Isatis tinctoria L. hydroalcoholic leaf extract

Anti-diabetes and neuroprotection potential and primary safety studies of Isatis tinctoria L. hydroalcoholic leaf extract | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Anti-diabetes and neuroprotection potential and primary safety studies of Isatis tinctoria L. hydroalcoholic leaf extract Noemi Nicosia, Inga Kwiecień, Marek Bednarski, Monika Głuch-Lutwin, and 11 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4208153/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 01 Jul, 2024 Read the published version in Fitoterapia → Version 1 posted You are reading this latest preprint version Abstract Objectives Natural plant raw materials, previously underestimated in therapeutics, are becoming the subject of research for new applications in medicine. In our research, the hydroalcoholic extract of Isatis tinctoria leaf, rich in flavonoid compounds such as vicenin-2 and quercetin, was examined as a potential antidiabetic and neuroprotective agent. Methods The effect of the extract and its main flavonoid compounds on protein glycation, alpha-glucosidase activity, and acetylcholinesterase activity was tested. In vitro , in the mouse hippocampal neuronal cell line and in vivo , using a mouse model, the safety of the extract was screened for. Key findings: Our experiments demonstrated significant inhibition of protein glycation, alpha-glucosidase activity, and acetylcholinesterase activity by the extract, in a concentration dependent manner. The extract had a strong reducing effect, did not exhibit cytotoxicity up to a concentration of 25 mg/mL. Intraperitoneal administration of the extract to mice did not have negative effects on body mass, locomotor activity, coordination, and liver cell integrity. Conclusions Our research sheds a new light on this raw material and deepens knowledge of its activity. This may result in the recognition of its therapeutic effects and even in its introduction in the modern treatment of diseases characterized by pathological changes associated with hyperglycemia, oxidation, and inflammation. Isatis tinctoria L vicenin-2 anti-diabetic neuroprotection cytotoxicity safety Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Figure 9 Figure 10 Figure 11 Figure 12 1. Introduction Diabetes mellitus (DM) is an endocrine disease characterized by dysfunctional metabolism of lipids and carbohydrates by insulin, a pancreatic hormone, leading to an increase in blood glucose levels [ 1 ]. DM is a global health crisis that deeply affects the personal, social, and physical well-being of the population. Current therapeutic strategies for glycaemic control include insulin and its analogues, sulphonylureas, biguanides, thiazolidinediones, and α-glucosidase inhibitors [ 2 ]. Glycation inhibitors are a potential drug class for the management of disorders caused by hyperglycemia, however, to date, none of the tested compounds (aminogluanidine was the closest to success) have undergone clinical trials [ 3 ]. Emerging evidence highlights the strong link between DM and Alzheimer’s disease (AD) and is lately often referred to as "type 3 diabetes", because of the crucial role of insulin in cognitive function and neurodegenerative processes involving memory elaboration and neuronal integrity [ 4 ]. The connection between the two pathologies is further complicated by inflammation, oxidative stress, and glycation, which are exacerbated in DM, in addition to significantly contributing to the development of AD [ 5 ]. Plant-derived drugs with antioxidant, anti-inflammatory and antibacterial properties have gained attention due to their numerous advantages, such as low toxicity, mild side effects, as well as multiple pharmacological targets [ 6 ]. Therefore, the search for natural products or phytochemicals is growing, with the possibility that they may become acceptable alternatives or complementary agents to existing pharmacological treatment [ 7 ]. In view of this, Isatis tinctoria L. (IT) is a plant of great interest as it exhibits various beneficial properties closely related to its phytochemical profile. It is well known for its use as a Chinese herb in the treatment of inflammatory diseases, viral and bacterial infections in Traditional Chinese Medicine [ 8 ]. Isatis tinctoria was recognized as a pharmacopoeial plant and introduced into official European phytomedicine in 2011 [ 9 ]. In the pharmacopoeial monograph, Isatis indigotica was listed as another name for Isatis tinctoria . This record was maintained until the current 10th edition of the European Pharmacopeia [ 10 ]. When describing Isatidis radix (BănLánGēn) and Isatidis folium (DàQīngYè), many of the researchers following the Chinese pharmacopoeia claim that these raw materials originate from I. indigotica [ 11 , 12 ]. Nevertheless, some new works consider them to be two different species [ 13 ]. Despite considering them as separate species, the European Pharmacopeia deems them to be equivalent for the purposes of obtaining the raw material. The European monograph concerns Isatidis radix . However, Isatidis folium is not included, which necessitates research into the biological activity of the leaf extract in animal models and into the safety of its use. Recently, the increasing demand for the use of IT for its medicinal properties has driven a renewed interest in the promising biological activities ascribed to its bioactive compounds, which include alkaloids, phenolic compounds, and glucosinolates [ 14 ]. As a result, in the last decade, extracts obtained from IT leaves and roots have been the subject of numerous phytochemical studies and investigations into their therapeutic potential in animal and human diseases [ 15 ]. Studies have mainly focused on analysing the lipophilic extract of IT and evaluating its strong anticancer and anti-inflammatory properties in various animal models [ 16 ]. Isolated compounds such as the alkaloids tryptanthrin, indolinone, and indirubin have been widely examined for their beneficial health effects [ 17 – 20 ]. However, to date, few investigations have been carried out on the biological activity of the polar constituents of this species [ 15 , 21 – 24 ]. The phenolic compounds of the hydroalcoholic extract (MeOH 70) of IT leaves were first characterized by Taviano et al., and next Miceli et al., revealed a strong correlation between antioxidant activity and flavonoids and phenolic acids [ 22 ]. Among the flavonoids identified in the said extract, vicenin-2 was the most abundant flavone, followed by isovitexin and apigenin glucosides, whereas quercetin was the most abundant flavonol. The polar extract showed good radical scavenging and ferrous ion chelating activity, as well as moderate reduction power, ascribed to the high concentration of flavonoids [ 21 ]. Interestingly, vicenin-2, also known as 6,8-di-C-glucoside of apigenin, has been reported to possess a wide variety of pharmacological activity including anti-cancer, anti-inflammatory, antioxidant, and hepatoprotective properties [ 25 ]. An in vivo study, conducted in a carrageen-induced rat paw oedema model, demonstrated that vicenin-2 blocks the production of inflammatory mediators such as tumor necrosis factor-α (TNF-α) and nitric oxide (NO) through the inhibition of nuclear factor-kB (NF-kB) [ 26 ]. In addition, interesting findings come from a study focusing on the antidiabetic potential of vicenin-2 as a result of the strong inhibition of α-glucosidase, aldose reductase, and protein tyrosine phosphatase 1B. These three enzymes have become important therapeutic targets in the treatment of diabetes mellitus [ 25 ]. Furthermore, a notably increasing number of studies highlight the therapeutic potential of apigenin, a natural flavone, in the management of neurodegenerative disorders. A recent experiment conducted in a rat model of AD, revealed the ability of apigenin to inhibit glycogen synthase kinase-3 beta, a molecule that plays a key role in the generation of amyloid beta plaques and neurofibrillary tangles, leading to neuroprotective effects [ 27 ]. Little information is available on the historical use of IT in European countries since its introduction to Europe from China and Japan in ancient times is only described by Hamburger [ 28 ]. The raw material used in the experiments in this work comes from natural sites in Italy and has been identified as Isatis tinctoria . In view of the absence of information on the action and activity of the European raw material, such studies are most needed and recommended. In our previous article, we showed that a single administration of IT hydroalcoholic leaf extract reverses anxiety-like behavior caused by the acute restraint stress paradigm through a mechanism partially dependent on the modulation of neuroinflammation, oxidative stress, and NO reduction [ 24 ]. In this manuscript, taking into account that IT hydroalcoholic leaf extract has high concentrations of vicenin-2 (6,8-di-C-glucoside of apigenin) or quercetin [ 21 ], which reduce protein glycation [ 25 , 29 ] and significantly inhibit the activity of enzymes involved in the breakdown of complex carbohydrates in the digestive tract, such as amylase [ 30 ] or alpha-glucosidase [ 25 , 31 ], we determined the impact of the tested extract on protein glycation and on alpha-glucosidase activity. We compared the effect of IT extract to the effect of its main active compounds, i.e., vicenin-2 and quercetin (Fig. 1 shows the structures of these compounds). Moreover, we examined the effect of the IT extract on acetylcholinesterase activity. We also assessed the in vitro and in vivo safety of IT hydroalcoholic leaf extract. Confirmation of safety is extremely important in the early-stage development of a therapeutic agent. Products that have significant side effects are excluded from further research, saving time, money, and lives of animals. Such screening using safety assays is necessary to select the appropriate doses for future testing in specific indications and to clearly confirm the potential for in vivo use. 2. Materials and Methods 2.1. Plant material The leaves were picked from IT growing in the wild around Acireale (Catania, Sicily, Italy). The dried plant material was extracted according to the procedure reported by Taviano et al. [ 22 ]. Finally, the hydroalcoholic extract (MeOH 70%) was evaporated to dryness in vacuum. The yield, referred to as 100g of dried plant material, was 24.32%. Prof. Salvatore Ragusa confirmed the taxonomic identity of the plant material. The specimens are deposited in the Herbarium of the Department of Scienze della Salute, University “Magna Graecia” of Catanzaro (Italy), under accession number no. 327/11. Phytochemical analysis of the extract was previously performed by HPLC-PDA-ESI-MS 2.2. In vitro protein glycation 2.2.1. Preparation of samples of glycated BSA The formation of glycated BSA was determined using the modified method of Vinson and Howard, 1996 [ 72 ], with minor modifications. In brief, BSA (10 mg/mL) in 100 mM sodium phosphate buffer (pH 7.4) was incubated with fructose solution (0.5mM), 0.02% sodium azide, (used to prevent bacterial growth), and the tested solutions. Quercetin was used as the reference compound. Only BSA in the same buffer without fructose was a blank. The reaction mixtures were incubated for twenty one days (at 37°C) and were then assayed to determine the quantity of advanced glycation end products. 2.2.2. Formation of advanced glycation end products The fluorescence intensity of the reaction products was determined using spectrofluorometric detector POLAR star Omega (BMG Labtech, Germany), wavelengths of excitation and emission: 340 nm, 440 nm. The results are presented as fluorescence intensity and are expressed as advanced glycation end products (AGEs) units: 1U = fluorescence of 0.5M fructose solution. 2.3. Alpha-glucosidase inhibition assay The effect of the tested extract on alpha-glucosidase activity was measured using a previously described method [ 25 ], with minor modifications. In brief, 100 µL of tested solution in 100 mM phosphate buffer (pH 6.8), 20 µL 0.2 U/mL alpha-glucosidase in 100 mM phosphate buffer (pH 6.8), and 100 µL of 100 mM phosphate buffer (pH 6.8) were added to a plate. The plate was incubated at 37°C for 15 min. The enzymatic reaction was initiated by the addition of 50 µL of 2.5 mM p-nitrophenyl alpha-D-glucopyranoside (p-NPG, Merck, Germany). The plate was incubated at 37°C for 20 min, and the reaction was stopped by adding 50 µL of 0.1 mol/L sodium carbonate solution.. The absorbance (λ = 405 nm) was measured using a plate reader (ThermoFisher Scientific, USA). Vicenin-2, quercetin and acarbose were used as reference compounds. The inhibition percentage was calculated using the formula: $$I \left[\%\right]= \frac{Ac-As}{Ac} \times 100\%$$ , where Ac is the absorbance of control, and As is absorbance of the sample. 2.4. Acetylcholineesterase inhibition assay The effect of the tested extract on acetylcholineesterase ( AchE) activity was measured as described by [ 29 ], with minor modifications. The reaction mixture contained: 60 µL of 100 mM sodium phosphate buffer (pH 8.2), 50 µL of the tested sample solution, 50 µL of 5,5′-dithiobis(2-nitrobenzoic acid) (6mM, Merck, Germany) and 20 µL of 0.5 U/mL AchE solution (Merck, Germany). It was incubated at room temperature (10 min). The reaction was initiated by the addition of 20 µL of acetylthiocholine iodide (25 mM, Merck, Germany). The absorbance was measured at λ = 412 nm after 5 min, using a plate reader (ThermoFisher Scientific, USA). The inhibition percentage was calculated using the formula: $$I \left[\%\right]=100-\left( \frac{As*100}{Ac} \right)$$ , where Ac is the absorbance of the control, and As is absorbance of the sample. Tactine, vicenin-2, and quercetin (Merck, Germany) were used as reference compounds. 2.5. Reduction assay (ferric reducing antioxidant power, FRAP) – in vitro The total antioxidant activity of the IT extract was determined by spectrophotometric determination of the reduced iron concentration. The assay was performed as described by Benzie and Strain [ 61 ] with some modifications [ 73 , 74 ]. The assay was carried out as follows 10 µL of the extract or solvent and 300 µL of the reagent were added to the following composition: ten parts of 0.3 M sodium acetate buffer (pH 3.7), one part of 2,4,6-tris(2-pyridyl)-s-triazine solution (0.01 M, Merck, Germany) and one part of FeCl 3 × 6 H 2 O solution (0.02 M). The absorbance was measured after 10 min of incubation (room temperature, 593 nm). Deionized water with FRAP solution was used as a blank. Ascorbic acid was used as the reference compound. The results for the tested extract were presented as the amount of reduced iron (III) ions. FeSO 4 × 7H 2 O salt was used for the construction of a standard curve (Fig. 2 ). 2.6. Cytotoxicity assay – in vitro The extract was tested at six concentrations ranging from 25 to 1 mg/mL using the mouse hippocampal neuronal cell line (HT-22). HT-22 were cultured in Dulbecco's modified Eagle's Medium-high glucose (DMEM, Glutamx, ThermoFisher Scientific, USA) supplemented with 10% heat inactivated fetal bovine serum (ThermoFisher Scientific, USA), 100 µg/mL streptomycin (Merck, Germany), and 100 IU/mL penicillin (Sigma Aldrich). The cells were placed in a 96-well culture plate (2x10 4 cells per well, Falcon) and were grown for 24 hours in the sterile condition (37°C, 5% CO 2 ). Subsequently, different concentrations of the extract were added and incubated for 24 hours. Cell viability was determined using both the Presto Blue and the ToxiLight assays. 2.6.1. Presto Blue assay The Presto Blue reagent (ThermoFisher Scientific, USA) was used to evaluation of cell viability [ 75 ]. After 24 hours of incubation with the extract, 10 µl of PrestoBlue reagent was added and incubated for 15 minutes at 37°C. The fluorescence intensity (wavelengths of excitation and emission: 340 nm, 440 nm) was measured in a plate reader (POLARstar Omega, BMG Labtech). The results were provided as the percentage of live cells with respect to the vehicle sample. 2.6.2. ToxiLight assay The ToxiLight reagent (Lonza, Switzerland), which measures membrane damage, was used to evaluation of cell viability [ 76 ]. It quantitatively measures the release of adenylate kinase from the membrane of damaged cells. After 24 hours of treatment, the supernatant was transferred to a new plate and the adenylate kinase detection reagent was added. Luminescence was measured after 5 minutes of incubation in a plate reader (POLARstar Omega, BMG Labtech). The results were provided as the percentage of damaged/lysed cells. 2.7. Animals All animal care and experimental procedures were carried out in accordance with the European Union and Polish legislation acts concerning animal experimentation and were approved by the Local Ethics Committee of Jagiellonian University of Cracow, Poland (Permissions No: 473/2020, date: 16.12.2020; No: 545B/2021, date: 21.07.2021). The animals were obtained from the Animal House of the Jagiellonian University Pharmaceutical Faculty. Six-week-old male Albino Swiss mice, CD-1, weighing 20–22 g, were used. They were kept in environmentally controlled rooms, in standard cages lit by artificial light for 12 hours per day. The animals had free access to food and water, except for during the acute experiment. The randomly established experimental groups consisted of 8 mice. 2.8. Extract dosage and administration schedule The extract was administered intraperitoneally (i.p.) to mice, at the following doses: 50 mg/kg, 100 mg/kg, or 500 mg/kg b.w. These are the same doses of Isatis tinctoria leaf extract described in our previous manuscript [ 24 ]. The vehicle (1% Tween 80; Sigma-Aldrich, Poland) was administered i.p. at a volume of 10 mL/kg. Thirty minutes after the first administration, the chimney and Rotarod tests were performed. Seven days later, 30 minutes after the second administration, locomotor activity was measured. Exactly one hour after administration of the extract, plasma was collected for biochemical testing. 2.9. Chimney test The mice were trained before the test and only those animals that could get out of the chimney in less than 1 minute were used in the experimental stage. The selected mice were placed in a horizontal tube (length 25cm, diameter 2.5cm), which was next set up vertical, in such a way that the mice could only exit by climbing backwards until they reached the other end. Motor impairment was established to be the inability of the mice to exit the tube within 60 seconds. The number of animals unable to climb backwards within 60 seconds was recorded and was expressed as the % of animals that could not climb out [ 77 ]. The mice were injected with the extract 30 minutes prior to the chimney test. 2.10. Rotarod test In brief, the mice were trained on the Rotarod apparatus (May Commat RR0711, Turkey; rod diameter: 2cm) prior to the experiment. During each training session, the mice were placed on the rotating rod (10 rpm, constant speed) twice for 3 minutes. The experiment was carried out 24 hours after the last training session. On the day of the test, the mice were injected with the extract, and 30 minutes after administration, tested on the chimney test, followed by the Rotarod test (10 rpm, constant speed). Motor impairment was regarded as the inability to remain on the rotating rod for 60 seconds and was expressed as the percentage of animals that fell off the rotating rod [ 78 ]. 2.11. Change of body weight after administration of the tested extract Mice were weighed prior to test extract administration and 24 hours after administration, on a weighing scale suitable for small animals (K-PZ Waagen, Germany). 2.12. Locomotor activity test after single administration of test extract Locomotor activity was individually recorded for each animal using specifically designed activity cages made of clear Perspex (40 cm × 40 cm × 31 cm, Activity Cage 7441, Ugo Basile, Italy). The cages were fitted with I.R. horizontal beam emitters connected to a counter, which records the light-beam interruptions. Prepared suspensions of the extract were administered as i.p. injections 30 minutes before testing. The control animals received i.p. injections of vehicles. Each mouse was placed in the cage for a 30-minute habituation period (immediately after administration). Afterwards, the number of photo beam interruptions was measured for 5 minutes, which is the same observation period used in other tests. 2.13. Plasma collection At the end of the experiment, 60 minutes after IT or vehicle administration and 20 minutes after ip administration of heparin (2500 units/mouse; Polfa Warszawa S.A., Poland), blood was collected after decapitation. It was centrifuged at 600 x g for 15 min (4°C) in order to obtain plasma. It was frozen in liquid nitrogen and placed in a freezer (-80°C) until biochemical assays were performed. 2.14. Biochemical analysis To determine alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (γGTP), alanine aminotransferase (AlaT), and asparagine aminotransferase (AspaT) activity in plasma, a standard enzyme spectrophotometric tests (Biomaxima S.A., Poland) were used. Absorbance was measured at a wavelength of 405 nm (ALP, γGTP) or 340 nm (AlaT, AspaT). 2.15. The Ferric Reducing Ability of Plasma (FRAP) - a measure of “Antioxidant Power” The assay was performed as described by Benzie and Strain [ 61 ] with some modifications [ 79 ]. The FRAP working solution was prepared before the start of the analysis, using 0.3 mol of acetate buffer (pH 3.6), 0.01 mol of 2,4,6-tripyridyl-s-triazine (Merck, Germany) in 0.04 mol of HCl (POCh, Poland) and 0.02 M FeCl 3 ×6H 2 O in water (iron III) (Chempur, Poland), which were mixed in a volumetric ratio of 10:1:1 and protected from light. Subsequently, 20 µL of the plasma sample tested, brain homogenate, or FeSO 4 ×7H 2 O solution was mixed with 180 µL of the FRAP working solution. The mixtures obtained were incubated at 37°C for 30 minutes and absorbance was measured at 593 nm. FeSO 4 ×7H 2 O (Chempur, Poland) was used to create a standard curve (100–1000 µmol/L). Deionized water containing FRAP solution was used as the blank. 2.16. Statistical analysis Statistical calculations were performed using GraphPad Prism 9 software (GraphPad Software, USA). Results are expressed as mean + standard deviation (SD) or mean + Δ/2, where Δ is a width of the 95% confidence interval (CI), n = 6–8. Statistical significance was calculated using one-way ANOVA, Dunnet or Tuckey post hoc test. Differences were considered statistically significant at: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 3. Results 3.1. Influence on bovine serum albumin (BSA) glycation IT extract caused a reduction in the formation of advanced glycation products (AGEs). Incubation of the extract at concentrations 25 mg/mL, 20 mg/mL and 15 mg/mL with BSA and 0.5M fructose solution for three weeks significantly reduced the formation AGEs compared to the control sample, i.e. BSA and 0.5M fructose. The results are shown in Fig. 3 . The active compound in the IT extract, vicenin-2, also significantly inhibited the glycation of BSA at concentrations 10 − 5 and 10 -6 M. Quercetin, the reference compound used, reduced the formation of AGEs to a comparable extent as vicenin-2. 3.2. Influence on alpha-glucosidase activity IT extract inhibited α-glucosidase activity in a concentration-dependent manner. The results are shown in Fig. 4 . The highest concentration of IT extract tested, 1 mg/mL, inhibited the activity of the enzyme by approximately 50%, and a concentration ten times lower inhibited it by less than 10%. This effect was stronger than that of the selected compounds - vicenin-2 and quercetin. The active compounds from the IT extract, vicenin-2 and quercetin, also inhibited α-glucosidase activity at concentrations 10 − 5 , 10 − 6 and 10 − 7 M. However, the effect was only about 15% at the highest concentration used (10 − 5 ) and was half as weak compared to the inhibition at the lowest concentration of acarbose used (10 − 7 ). Additionally, inhibition by the IT extract was about 5.5 times weaker in comparison to the inhibition at the same concentration by acarbose (10 − 5 ). Acarbose, the reference compound used, inhibited α-glucosidase activity in a concentration-dependent manner. 3.3. Influence on acetylcholinesterase (AchE) activity IT extract inhibited acetylcholinesterase activity at all the tested concentrations. The results are shown in Fig. 5 . At the highest concentration, 1 mg/mL, the IT extract inhibited the activity of the enzyme by approximately 25%, at half the maximum concentration it inhibited the activity of AchE by about 20%, and at lower concentrations, 0.25 mg/mL and 0.1 mg/mL, inhibition was below 5%. The inhibitory activity determined for the two highest concentrations of IT extract was similar to that of the selected compounds - vicenin-2 and quercetin, at concentrations 10 − 4 to 10 − 6 , but lower than inhibitory activity of tacrine. The active compounds from the IT extract, vicenin-2 and quercetin, inhibited AchE activity at concentrations 10 − 4 , 10 − 5 and 10 − 6 M. However, this effect was only about 30 − 20% at the highest concentration used (10 − 4 ) and was weak compared to activity of tacrine at the same concentration. Tacrine, the reference compound used, inhibited AchE activity in a concentration-dependent manner. 3.4. Toxicity Study and Antioxidant Assays 3.4.1. Cytotoxicity The extract was not cytotoxic at all the concentrations tested. Cell viability was determined using the Presto Blue assay, the number of cells in the control (vehicle, water) being 100% live cells (Fig. 6 a) and in the ToxiLight assay, 100% damaged cells being present in the lysis sample (Fig. 6 b). 3.4.2. Reduction activity In the FRAP assay, IT extract caused a concentration-dependent reduction of iron (III) ions. 1 gram of extract reduced 60 mmol Fe 3+ to 140 mmol (Fig. 7 a). Ascorbic acid was used as the reference compound. An increase in absorbance, proportional to the concentration of reduced iron (0.1–1 mM) was determined, indicating an increase in total antioxidant activity. The maximum activity of ascorbic acid occurred a concentration of 1 mM (Fig. 7 b). 3.5 Influence on the body mass of mice The tested extracts did not have a significant effect on the body mass of mice during a 24-hour period, after one intraperitoneal administration. The results are shown in Fig. 8 . 3.6 Influence on the locomotor activity of mice The locomotor activity of mice decreased significantly after administration of 50 mg/kg b.w. (F(3.28) = 3.948, p = 0.0182, n = 8 of IT leaves extract). The results are shown in Fig. 9 . 3.7 Influence on motor coordination IT extract did not affect motor coordination in the Rotarod and chimney tests. Results are shown in Table 1 . Only one mouse from the group treated with IT extract at a dose of 100 mg/kg b.w. did not exit the chimney within 1 minute. However, we observed that in this group, the exit times were significantly longer compared to the control group (F(3,20) = 2.697, p = 0.0733, n = 6). We assigned a time of 60 seconds to the mouse that did not come out of the chimney. Results are shown in Fig. 10 . Table 1 The effect of IT on motor coordination in the Rotarod and Chimney test in mice. Treatment Rotarod test [% of animals that could not stay on a rotating rod for at least 1 minute] Chimney test [% of animals that did not climb out after 1 minute] 1% Tween 80 0 0 IT 500 mg/kg 0 0 IT 100 mg/kg 0 16.67 IT 50 mg/kg 0 0 IT – Isatis tinctoria extract. n = 6 animals per group. 3.8 Influence on hepatic enzyme activity in plasma After administration of IT extract only a significant increase in alkaline phosphatase (AP) activity was determined in comparison to the plasma activity determined for the control group (F(3,28) = 3.414, p = 0.0310, n = 8). The activity of the other enzymes determined in plasma of the treated group were comparable to the activity of these enzymes in the plasma of the control group. Results are shown in Fig. 11 . 2.9 Influence on the total antioxidant activity of plasma The extract of IT leaves administered to mice at a dose of 500 mg/kg b.w. had a significant antioxidant effect one hour after intraperitoneal administration (F(3, 28) = 7.116, p = 0.0011, n = 8). Results are shown in Fig. 12 . 4. Discussion Our research demonstrates the anti-diabetic and neuroprotective potential of Isatis tinctoria L. hydroalcoholic leaf extract for the first time. It shows that the effect of the extract on the reduction of protein glycation is significant. Additionally, IT extract inhibits alpha-glucosidase activity in a concentration dependent manner and AchE activity at some concentrations. We also show the results of preliminary in vivo safety studies and show that intraperitoneal administration of hydroalcoholic extract of IT leaf at doses from 50 mg/kg b.w. to 500 mg/kg, is most likely safe for the organism. Moreover, the tested extract has no cytotoxic properties, even at concentrations characterized by a strong reducing effect. Neurodegenerative, cardiovascular, and metabolic diseases have a significant negative effect on the quality of life and life span of the aging population. The increased accumulation of damaged proteins is responsible for the formation of bulky aggregates and plaques typical of the aforementioned diseases. Type 2 DM is one of the most important risk factors responsible for age-related cognitive impairment [ 32 ]. The pathophysiology of AD is attributed to numerous factors such as cholinergic dysfunction, amyloid/tau toxicity and oxidative stress/mitochondrial dysfunction [ 33 ]. Interestingly, clinical evidence considers hyperglycemia to be one of the risk factors for the development and progression of AD [ 34 ]. Consequently, plant products that inhibit AchE activity, alpha-glucosidase activity, and protein glycation, in addition to exhibiting antioxidant properties, have anti-diabetic and neuroprotective potential. Numerous medicinal herbs and dietary plants, containing polyphenols, were found to prevent protein glycation in in vitro studies [ 35 – 38 ]. The anti-glycating activity of many flavonoids, including quercetin, quercitrin, genistein, kaempferol, naringin, rutin, and propyl gallate, has been documented [ 39 – 44 ]. Phenolic acids could effectively protect BSA from glycation in vitro [ 45 – 48 ]. The IT extract we chose for our research contains many different compounds in various concentrations, including e.g.: vicenin-2 (7.51 mg/g), flavone-di-glucoside (6.42 mg/g), isovitexin (5.46 mg/g), stellarin-2 (4.69 mg/g), apigenin-di-glucoside (4.51 mg/g), apigenin-glucoside (4.68 mg/g), isoscoparin (3.89 mg/g), quercetin (1.86 mg/g), neochlorogenic acid (1.84 mg/g), sinapic acid (1.49 mg/g) and kaempferol (1.48 mg/g) [ 21 ]. Some of these compounds have proven anti-glycation and antioxidant activity; and an inhibitory effect on some enzyme activity, e.g. alpha-glucosidase or AchE. Despite the inhibition of protein glycation by the extract being less intense than the inhibition exerted by the main compounds (vicenin-2 and quercetin) of this extract at the tested concentrations, it is still detectable. Earlier studies clearly demonstrate that the accumulation of advanced glycation end products (AGEs) in tissue is the leading cause of age-related degeneration, atherosclerosis, and diabetic complications such as neuropathy, retinopathy, cardiomyopathy, and nephropathy [ 49 , 50 ]. Recent studies suggest that AGEs interact with specific receptors (RAGE) in the plasma membrane, modifying gene expression, changing intracellular signal transmission, and promoting the release of free radicals and pro-inflammatory molecules [ 51 , 52 ]. Therefore, inhibition of AGE formation is a potential therapeutic target for preventing the progression of the aforementioned complications of diabetes and protecting against the development of age-related cognitive impairment and neurodegenerative disorders. Alpha-glucosidase is an enzyme located in the digestive tract which is responsible for breaking down carbohydrates to facilitate the absorption of monosaccharides. Inhibition of alpha-glucosidase activity can reduce diabetic complications [ 53 , 54 ], making its inhibition by the main compounds in IT, vicenin-2, quercetin, of great value [ 25 ]. In our study, IT leaf extract was more active than these compounds at almost all the tested concentrations. The inhibition of alpha-glucosidase shows the potential of IT extract in the management of hyperglycemic states, diabetes, obesity, and neurodegenerative diseases. AchE plays a key role in the hydrolysis of acetylcholine in the regulation of cholinergic neurotransmission [ 55 ]. Inhibitors of this enzyme can delay the progress of mental illness, thus providing a rational therapeutic alternative in the treatment of Alzheimer’s disease. Our study shows that IT extract has a weak inhibitory effect on AchE. Vicenin-2 and quercetin also possess weak activity in this regard. The effect on AchE activity can be considered as an additional benefit of this extract in the management of neurodegenerative disorders. A limitation of our study is the difficulty in drawing a direct comparison between the potency of the extract and the potency of the main compounds. For that reason, we consider the results to be preliminary, since the main compounds isolated from IT and the reference compounds (acarbose, tacrine) were used in molar concentrations so that their activity could be compared, which cannot be done for the extract. Few in vivo studies showing the effects of various IT leaf extracts on the organism are presented in the literature [ 20 , 24 , 56 , 57 ], and these mainly concern their anti-inflammatory effect. Moreover, most of the manuscripts focus on the in vitro activities of the various extracts of this plant with interesting therapeutic properties [ 15 , 21 , 58 ]. Oxidative stress is characteristic of many diseases including, type 2 diabetes mellitus, atherosclerosis, hypertension, chronic obstructive pulmonary disease, major depression, Alzheimer's disease, inflammation, and cancer, making the development of effective antioxidant therapies of great importance [ 59 ]. Free radicals are oxidizing agents, causing tissue damage. Uncontrolled oxidative activity is the basis of various pathological conditions and can be countered by antioxidant treatment. Nonetheless, oxidants may exert beneficial effects by regulating cell signaling cascades [ 60 ]. In an in vitro study, we demonstrated the absence of cytotoxic activity by the tested extract on HT-22 cells, even at concentrations with significant reducing power. Subsequently, in plasma collected from animals, we determined the plasma reduction force by determining the reduction force of Fe3 + ions, which is interpreted as the total antioxidant force of plasma [ 61 ]. IT extract administered to mice at a dose of 500 mg/kg b.w. had a significant antioxidant effect one hour after a single intraperitoneal administration. This is an important property of the extract in vivo . From the simple measurements of basal body weight after administration of the plant extract/compound, basic conclusions on the effects on the organism can be drawn. Since animals that feel somehow unwell after the administration of an agent have reduced locomotor activity [ 62 , 63 ], and consume less food, they may lose significant body mass. Weight loss can also be the result of increased activity and calorie expenditure. It should be noted that such changes in the mice can be noticed in a short timeframe because they constantly consume food throughout the day [ 64 ]. Furthermore, it is worth noting that body weight is a dynamic parameter and that daily fluctuations, are within the range of approximately 2–3% (in control animals). In our research, we measured body weight prior to and 24 hours after the administration of IT extract, weighed the amount of food consumed, and measured the influence on locomotor activity. The extract tested did not have a significant effect on mouse body weight. Interestingly, after administration of the extract at doses of 500 and 50 mg/kg b.w., a slight decrease in body weight was established. In all groups, the mice ate a similar amount of food within 24 h, that is, 20g/24h/6 mice ± 1 g. However, locomotor activity, after administration of the leaf extract at a dose of 50 mg/kg b.w., significantly decreased in comparison to the spontaneous activity determined in the control group. This observed decrease in activity could explain the slightly lower weight gain observed in this group after administration of the extract. A limitation of these studies is s the short time (5 minutes) allocated to determination of the effect of IT extract on spontaneous activity, therefore further studies should be carried out to monitor spontaneous activity for e.g., 24 hours after administration of the tested extracts. An interesting result is that IT extract only has a sedative effect at the lowest dose used. These differences in the effect on spontaneous activity may be attributed to the differences in the action of the compounds in the extract at different concentrations. At lower doses, certain compounds may have significant activity (sedation), whereas, at higher doses, other compounds may become active and suppress or counteract the effects of the compounds acting at lower doses. In our previous research, we demonstrated that IT hydroalcoholic leaf extract can reduce stress-induced behavioral disturbances by regulation of neuro-nitrosative, neuro-oxidative, and neuroimmune pathways [ 24 ]. However, given the reports, some centrally acting compounds or drugs, e.g.: antidepressants, stress relievers, and anxiolytics, may negatively affect motor coordination [ 65 , 66 ]. In view of this, we conducted preliminary safety studies to reduce the use of animals later on, since products that disturb motor coordination are excluded from further studies. The results obtained from the motor coordination tests clearly show that at the doses used, the IT extract does not significantly disturb the motor coordination of mice. However, it should be taken into account that at a dose of 100 mg/kg b.w., the extract significantly prolonged the time of exit of mice from the chimney compared to the time of exit from the chimney of the control mice - which suggests that at this dose, the activity of the compounds in the extract is the least safe. This coincides with the observations described in the earlier manuscript, where a dose of 100 mg/kg b.w. was considered the least favorable [ 24 ]. As part of the safety studies conducted, we also performed assays on plasma collected from animals to determine the activity of enzymes such as gamma-glutamyl transpeptidase (gGT), alkaline phosphatase (AP), alanine aminotransferase (AlaT), and aspartate aminotransferase (AspaT). These were done to check the acute effect of the tested extracts on liver cells (liver integrity or hepatocellular damage). Liver toxicity is one of the most common difficulties encountered in drug development. However only 43% of the toxicities seen in rodents are observed humans, as was established by a retrospective study on the toxicity of pharmaceuticals in development [ 67 ]. Enzymes synthesized in cells perform specific functions intracellularly, and few are secreted into the extracellular space. Each tissue has its own specific enzyme profile. The presence of intracellular enzymes in body fluids may indicate tissue damage (damage to the cell membrane – reversible, or cell breakdown - irreversible). The current best-practice recommendation for nonclinical safety assessment is that a minimum of four serum parameters is used to assess hepatocellular (a minimum of two markers) and hepatobiliary (a minimum of two markers) injury [ 68 , 69 ]. Any two markers of glutamate dehydrogenase activity, sorbitol dehydrogenase activity, alanine transaminase activity, and aspartate transaminase activity, can be used to evaluate hepatocellular injury, whilst any two of gamma-glutamyl transferase activity, alkaline phosphatase activity, total bile acids and 5′-nucleotidase, total bilirubin can be used to assess hepatobiliary injury [ 70 ]. In our study, we determined the activity of four enzymes in plasma 60 minutes after administration of the test extract, similarly as other authors earlier [ 71 ]. After administration of the IT extract, only a significant increase in AP activity was determined in comparison to the activity determined for the control group. This difference was only observed at a dose of 100 mg/kg b.w. ip. Since plasma levels of AP increase as the patency of the bile duct is reduced, AP is widely used in nonclinical and human clinical settings as a marker of cholestatic liver injury [ 70 ]. In the absence of an increase in the other measured enzymes, especially gGT, hepatic disorders are excluded. It is known that fluctuations of AP need to be interpreted cautiously in nonclinical settings since there is an intestinal isoform of AP whose activity transiently increases postprandially [ 68 ]. 5. Conclusions The presented preliminary studies show that IT hydroalcoholic leaf extract exhibits antiglycation, anti-alpha-glucosidase, anti-AchE, antioxidant, anti-inflammatory properties and therefore also has anti-diabetic and neuroprotective potential. Additionally, in vitro , and in vivo safety studies in mice confirm that the tested extract does not cause coordination disorders and does not significantly affect body mass and liver enzyme activity. Depending on the dose used, it can have a sedative effect (which may be beneficial in some conditions). It has no cytotoxic effect on hippocampal cells, even at concentrations with significant reducing power. Therefore, hydroalcoholic extract of this plant may be considered for further research in the management of disorders linked to oxidative stress. Declarations Author Contributions: Conceptualization, and methodology, M.K.; formal analysis, M.K., N.N., M.B., M. G-L., R.H., P.Z., A.M., E.T.; investigation, M.K., N.N., M.B.; resources, I.K., N.M., S.R.; data curation, M.K.; writing - original draft preparation, M.K., N.N., M.B., M.G-L., I.K., K.M.; writing - review and editing, M.K., P.Z., N.N., A.A, I.K., N.M., E.R.L., J.S.; project administration, M.K.; visualization, M.K; funding acquisition, M.K., I.K.; supervision, M.K., I.K.; All authors have read and agreed to the published version of the manuscript. Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Local Ethics Committee for Experiments on Animals of the Jagiellonian University in Krakow (Permissions No: 473/2020, date: 16.12.2020; No: 545B/2021, date: 21.07.2021). Funding: This work was supported by statutory funds (No N42/DBS/000285) from the Faculty of Pharmacy, Jagiellonian University, Medical College, Krakow, Poland. Acknowledgments: Noemi Nicosia thanks the Prof. Antonio Imbesi Foundation for the fellowship. Paula Zammit thanks the Erasmus+ Program for a scholarship at the Jagiellonian University. HT-22 was a generous gift from Dr. Bartosz Pomierny of the Department of Biochemical Toxicology, Jagiellonian University Medical College, Krakow, Poland - the authors thank him very much for it. Conflicts of Interest: All authors declare that they have no conflicts of interest. Sample Availability: The Isatis tinctoria L. hydroalcoholic leaf extract was earlier characterized to full details of the chemical composition. The data have been presented in previous manuscripts (see Miceli et al., 2017[21], Taviano et al., 2018 [22]). Samples of the extract are available from the authors. Data availability statement: The data that support the findings of this study are available from the corresponding author upon reasonable request. References Dilworth L, Facey A, Omoruy F (2021) Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues. Int J Mol Sci 2214:7644. 10.3390/ijms22147644 Kashtoh H, Baek KH (2022) Recent Updates on Phytoconstituent Alpha-Glucosidase Inhibitors: An Approach towards the Treatment of Type Two Diabetes. Plants 1120:2722. 10.3390/plants11202722 Thornalley PJ (2003) Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419(1):31–40. 10.1016/j.abb.2003.08.013 Neth BJ, Craft S (2017) Insulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages. Front Aging Neurosci 9:345. 10.3389/fnagi.2017.00345 Janoutová J, Machaczka O, Zatloukalová A, Janout V (2022) Is Alzheimer’s disease a type 3 diabetes? A review. Cent Eur J Public Health 30:139–143. 10.21101/cejph.a7238 Xu J, Lan Z, Wang S, Guo Y, Ning J, Song Y, Liu M, Tian C (2022) The pharmaceutical applications of total flavonoids extract from Isatis tinctoria L. leaves. Pharm Research-Modern Chin Med 3:100122. 10.1016/j.prmcm.2022.100122 Lee SW, Cho YW (2019) Anti-Inflammatory Effect of the Isatis tinctoria L. Root Extract on Lipopolysaccharide-Induced Periodontitis in Rats. J Bio Med 7:09: 81. 10.4236/jbm.2019.79008 Kim EJ, Woo J, Shin S, Choi H, Kim Y, Kim J, Kang C (2022) A focused natural compound screen reveals senolytic and senostatic effects of Isatis tinctoria. Anim Cells Syst 310–317. 10.1080/19768354.2022.2143895 European Pharmacopeia 7th ed. Supple. 7.3 (2566); Isatis root ( Isaditis radix ), 2011, European Directorate for the Quality of Medicines: Strasburg, Germany, pp. 3866–3867 European Pharmacopeia, 11th ed.; Isatis root (Isaditis radix) (2022) European Directorate for the Quality of Medicines: Strasburg, Germany, pp. 1568–1569 Chen Q, Lan HY, Peng W, Rahman K, Liu QC, Luan X, Zhang H (2021) Isatis indigotica : a review of phytochemistry, pharmacological activities and clinical applications. J Pharm Pharmacol 739:1137–1150. 10.1093/jpp/rgab014 Pharmacopoeia of the People’s Republic of China, 11th edition (2020) Chemical Industry Press, Beijing, China Nie LX, Dong J, Huang LY, Qian XY, Lian CJ, Kang S, Dai Z, Ma SC (2021) Microscopic Mass Spectrometry Imaging Reveals the Distribution of Phytochemicals in the Dried Root of Isatis tinctoria. Front Pharmacol 12:685575. 10.3389/fphar.2021.685575 Speranza J, Miceli N, Taviano MF, Ragusa S, Kwiecień I, Szopa A, Ekiert H (2020) Isatis tinctoria L. (Woad): A review of its botany, ethnobotanical uses, phytochemistry, biological activities, and biotechnological studies. Plants 93:298. 10.3390/plants9030298 Ragusa M, Miceli N, Piras C, Bosco A, Castagna F, Rinaldi L, Musella V, Taviano FM, Britti D (2022) In Vitro Anthelmintic Activity of Isatis tinctoria Extracts against Ewes’ Gastrointestinal Nematodes (GINs), a Possible Application for Animal Welfare. Vet Sci 93:129. 10.3390/vetsci9030129 Nguyen T, Marcelo P, Gontier E, Dauwe R (2019) Metabolic markers for the yield of lipophilic indole alkaloids in dried woad leaves ( Isatis tinctoria L). Phytochem 163:89–98. 10.1016/j.phytochem.2019.04.006 Steriti RND (2002) Nutritional support for chronic myelogenous and other leukaemias: a review of the scientific literature. Altern Med Rev 75:404–409 Eisenbrand G, Hippe F, Jakobs S, Muehlbeyer S (2004) Molecular mechanisms of indirubin and its derivatives: Novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol 130:627–635. 10.1007/s00432-004-0579-2 Recio MC, Cerdá-Nicolás M, Potterat O, Hamburger M, Ríos JL (2006) Anti-Inflammatory and Antiallergic Activity in vivo of Lipophilic Isatis tinctoria Extracts and Tryptanthrin. Planta Med 7206:539–546. 10.1055/s-2006-931562 Recio MC, Cerdá-Nicolás M, Hamburger M, Rios LJ (2006) Anti-arthritic activity of a lipophilic woad ( Isatis tinctoria ) extract. Planta Med 72 08:715–720. 10.1055/s-2006-941507 Miceli N, Filocamo A, Ragusa S, Cacciola F (2017) Chemical Characterization and Biological Activities of Phenolic-Rich Fraction from Cauline Leaves of Isatis tinctoria L. (Brassicaceae) Growing in Sicily, Italy. Chem Bio 14:8: e1700073. 10.1002/cbdv.201700073 Taviano MF, Filocamo A, Ragusa S, Cacciola F, Dugo P, Modello L, Mastrazzo PG, De Rose RF, Celano M, Lombardo GE, Melchini A, Miceli N (2018) Phenolic profile, antioxidant and cytotoxic properties of polar extracts from leaves and flowers of Isatis tinctoria L. (Brassicaceae) growing in Sicily. Plant Biosyst 1524:795–803. 10.1080/11263504.2017.1338629 Adawara SN, Shallangwa GA, Mamza P, Ibrahim A (2020) Anti-dengue potential, molecular docking study of some chemical constituents in the leaves of Isatis tinctoria . Chem Rev Lett 33:104–109. 10.22034/CRL.2020.228931.1054 Nicosia N, Kwiecień I, Mazurek J, Mika K, Bednarski M, Miceli N, Ragusa S, Ekiert H, Maes M, Kotańska M (2022) Hydroalcoholic Leaf Extract of Isatis tinctoria L. via Antioxidative and Anti-Inflammatory Effects Reduces Stress-Induced Behavioral and Cellular Disorders in Mice. Oxid Med Cell Longev 2022:3567879. 10.1155/2022/3567879 Islam MN, Ishita IJ, Jung HA, Choi JS (2014) Vicenin 2 isolated from Artemisia capillaris exhibited potent anti-glycation properties. Food Chem Toxicol 69:55–62. 10.1016/j.fct.2014.03.042 Marrassini C, Davicino R, Acevedo C, Anesini C, Gorzalczany S, Ferraro G (2011) Vicenin-2, a potential anti-inflammatory constituent of Urtica circularis . J Nat Prod 746:1503–1507. 10.1021/np100937e Alsadat AM, Nikbakht F, Nia HH, Golab F, Khadem Y, Barati M, Vazifekhah S (2021) GSK-3β as a target for apigenin-induced neuroprotection against Aβ 25–35 in a rat model of Alzheimer's disease. Neuropeptides 90:102200. 10.1016/j.npep.2021.102200 Hamburger M (2002) Isatis tinctoria - From the rediscovery of an ancient medicinal plant towards a novel anti-inflammatory phytopharmaceutical. Phytochem Rev 1:333–344 Choi JS, Islam MN, Ali MY, Kim EJ, Kim YM, Jung HA (2013) Effect of C-glycosylation on anti-diabetic, anti-Alzheimer’s disease, and anti-inflammatory potential of apigenin. Food Chem Tox 64:27–33. 10.1016/j.fct.2013.11.020 Zhou Y, Jiang Q, Ma S, Zhou X (2021) Effect of quercetin on the in vitro Tartary buckwheat starch digestibility. Int J Biol Macromol 183:818–830. 10.1016/j.ijbiomac.2021.05.013 Li YQ, Zhou FC, Gao F, Bian JS, Shan F (2009) Comparative evaluation of quercetin, isoquercetin and rutin as inhibitors of alpha-glucosidase. J Agric Food Chem 5724:11463–11468. 10.1021/jf903083h Sadowska-Bartosz I, Bartosz G (2016) Effect of glycation inhibitors on aging and age-related diseases. Mech Ageing Dev 160:1–18. 10.1016/j.mad.2016.09.006 Mohamed T, Shakeri A, Rao PP (2016) Amyloid cascade in Alzheimer's disease: Recent advances in medicinal chemistry. Eur J Med Chem 113:258–272. 10.1016/j.ejmech.2016.02.049 Craft S, Dagogo-Jack SE, Wiethop BV, Murphy C, Nevins RT, Fleischman S, Rice V, Newcomer JW, Cryer PE (1993) Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci 107:926–940. 10.1037/0735-7044.107.6.926 Ahmad H, Khan I, Wahid A (2012) Antiglycation and antioxidation properties of Juglans regia and Calendula officinalis: Possible role in reducing diabetic complications and slowing down ageing. J Tradit Chin Med 32:411–414. 10.1016/S0254-6272(13)60047-3 Jang DS, Yoo NH, Kim NH, Lee YM, Kim CS, Kim J, Kim JH, Kim JS (2010) 3,5-Di-O-caffeoyl-epi-quinic acid from the leaves and stems of Erigeron annuus inhibits protein glycation, aldose reductase, and cataractogenesis. Biol Pharm Bull 33:329–333. 10.1248/bpb.33.329 Harris CS, Cuerrier A, Lamont E, Haddad PS, Arnason JT, Bennett SA, Johns T (2014) Investigating wild berries as a dietary approach to reducing the formation of advanced glycation endproducts: Chemical correlates of in vitro antiglycation activity. Plant Foods Hum Nutr 6:71–77. 10.1007/s11130-014-0403-3 Ramkissoon JS, Mahomoodally MF, Ahmed N, Subratty AH (2013) Antioxidant and anti-glycation activities correlate with phenolic composition of tropical medicinal herbs. Asian Pac J Trop Med 6:561–569. 10.1016/S1995-7645(13)60097-8 Lv L, Shao X, Chen H, Ho CT, Sang S (2011) Genistein inhibits advanced glycation product formation by trapping methylglyoxal. Chem Res Toxicol 24:579–586. 10.1016/S1995-7645(13)60097-8 Bournival J, Francoeur MA, Renaud J, Martinoli MG (2012) Quercetin and sesamin protect neuronal PC12 cells from high-glucose-induced oxidation; nitrosative stress; and apoptosis. Rejuvenation Res 15:322–333. 10.1089/rej.2011.1242 Sadowska-Bartosz I, Galiniak S, Bartosz G (2014a) Kinetics of glycoxidation of bovine serum albumin by methylglyoxal and glyoxal and its prevention by various compounds. Molecules 19:4880–4896. 10.3390/molecules19044880 Sadowska-Bartosz I, Galiniak S, Bartosz G (2014b) Kinetics of glycoxidation of bovine serum albumin by glucose, fructose and ribose and its prevention by food components. Molecules 19:18828–18849. 10.3390/molecules191118828 Xie Y, Chen X (2013) Structures required of polyphenols for inhibiting advanced glycation end products formation. Curr Drug Metab 14:414–431. 10.2174/1389200211314040005 Sasaki K, Chiba S, Yoshizaki F (2014) Effect of natural flavonoids: Stilbenes and caffeic acid oligomers on protein glycation. Biomed Rep 2:628–632. 10.3892/br.2014.304 Adisakwattana S, Sompong W, Meeprom A, Ngamukote S, Yibchok-Anun S (2012) Cinnamic acid and its derivatives inhibit fructose-mediated protein glycation. Int J Mol Sci 13:1778–1789. 10.3390/ijms13021778 Silván JM, Assar SH, Srey C, Del Castillo MD, Ames JM (2011) Control of the Maillard reaction by ferulic acid. Food Chem 128:208–213. 10.1016/j.foodchem.2011.03.047 Sompong W, Meeprom A, Cheng H, Adisakwattana S (2013) A comparative study of ferulic acid on different monosaccharide-mediated protein glycation and oxidative and oxidative damage in bovine serum albumin. Molecules 18:13886–13903. 10.3390/molecules181113886 Meeprom A, Sompong W, Chan CB, Adisakwattana S (2013) Isoferulic acid, a new anti-glycation agent, inhibits fructose- and glucose-mediated protein glycation in vitro. Molecules 18:6439–6454. 10.3390/molecules18066439 Schmidt AM, Bakhti M (2000) Alherosclerosis and diabetes: The RAGE connection. Curr Atheroscler Rep 2:430–436. 10.1007/s11883-000-0082-4 Brownlee M (1995) Advanced protein glycosylation in diabetes and aging. Annu Rev Med 146:223–234. 10.1146/annurev.med.46.1.223 Shen CY, Lu CH, Wu CH, Le KJ, Kuo YM, Hsieh SC, Yu CL (2020) The development of Maillard reaction, and advanced glycation end product (AGE)-receptor for AGs (RAGE) signaling inhibitors as novel therapeutic strategies for patients with age-related diseases. Molecules 25:5591. 10.3390/molecules25235591 Chukwuma CI, Islam S (2015) Effects of xylitol on carbohydrate digesting enzymes activity, intestinal glucose absorption and muscle glucose uptake: a multi-mode study. Food Funct 6:955. 10.1039/c4fo00994k Bojarova P, Kren V (2009) Glicosidases: a key to tailored carbohydrates. Trends Biotechnol 27:199–209. 10.1016/j.tibtech.2008.12.003 Asano N (2003) Glycosidase inhibitors: update and perspectives on practical use. Glycobiology 13:93–104. 10.1093/glycob/cwg090 Silman I, Sussman JL (2008) Acetylcholinesterase: how is structurerelated to function? Chem Biol Interact 175:3–10. 10.1016/j.cbi.2008.05.035 Brattström A, Schapowal A, Kamal MA, Maillet I (2010) The plant extract Isatis tinctoria L. extract (ITE) inhibits allergen-induced airway inflammation and hyperreactivity in mice. Phytomedicine 17:551–556. 10.1016/j.phymed.2009.11.003 Jiang L, Lu Y, Jin J, Dong L, Xu F, Chen S, Wang Z, Liang G, Shan X (2015) n-Butanol extract from Folium isatidis inhibits lipopolysaccharide-induced inflammatory cytokine production in macrophages and protects mice against lipopolysaccharide-induced endotoxic shock. Drug Des Devel Ther 9:5601–5609. 10.2147/DDDT.S89924 Danz H, Stoyanova S, Wippich P, Brattström A, Hamburger M (2001) Identification and isolation of the cyclooxygenase-2 inhibitory principle in Isatis tinctoria . Planta Med 67:411–416. 10.1055/s-2001-15805 Forman HJ, Zhang H (2021) Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug Discov 20:689–709. 10.1038/s41573-021-00233-1 Di Meo S, Venditti P, Reed TT, Victor MV (2018) Harmful and Beneficial Role of ROS 2017. Oxid Med Cell Longev 2018:5943635. 10.1155/2018/5943635 Benzie I, Strain J (1999) Direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic. Enzymology 299:15–27. 10.1016/s0076-6879(99)99005-5 Reiter LW, MacPhail RC (1979) Motor activity: a survey of methods with potential use in toxicity testing. Neurobehav Toxicol 1:53–66 Lynch JJ, Castagné V, Moser PC, Mittelstadt WS (2011) Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies. J Pharma Tox Meth 64:74–80. 10.1016/j.vascn.2011.03.003 Claassen V (1994) Neglected factors in pharmacology and neuroscience research. Food and water intake. In: Hudson JP (ed) Techniques in the Behavioral and Neural Sciences, vol 12. Elsevier, Amsterdam, pp 267–287. Chap. 12 Strömberg C (1988) Interactions of antidepressants and ethanol on spontaneous locomotor activity and rotarod performance in NMRI and C57BL/6 mice. J Psychopharmacol 2:61–66. 10.1177/026988118800200201 Szkutnik-Fiedler D, Kus K, Balcerkiewicz M, Grześkowiak E, Nowakowska E, Burda K, Ratajczak P, Sadowski C (2012) Concomitant use of tramadol and venlafaxine: Evaluation of antidepressant- like activity and other behavioral effects in rats. Pharmacol Rep 64:1350–1358. 10.1016/s1734-1140(12)70932-5 Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Duen K, Smith P, Berger B, Heller A (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56–67 Boone L, Meyer D, Cusick P, Ennulat D, Bolliger A, Everds N, Meador V, Elliott G, Honor D, Bounous D, Jordan H (2005) Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet Clin Path 34:182–188. 10.1111/j.1939-165x.2005.tb00041.x Vuppalanchi R, Chalasani N (2018) Laboratory Tests in Liver Disease. In: Saxena R (ed) Practical Hepatic Pathology: A Diagnostic Approach. Elsevier, Philadelphia, PA, USA, pp 43–53 Aulbach A, Amuzie CJ (2017) Biomarkers in Nonclinical Drug Development. In: A Comprehensive guide to toxicology in nonclinical drug development. Academic Press, pp 447–471 Jarsiah P, Nosrati A, Alizadeh A, Hashemi-Soteh S (2017) Hepatotoxicity and ALT/AST Enzymes Activities Change in Therapeutic and Toxic Doses Consumption of Acetaminophen in Rats. Int Biol Biomed J 3:119–124 Vinson JA, Howard TBIII (1996) Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. J Nutr Biochem 7:659–663. 10.1016/S0955-2863(96)00128-3 Kotańska M, Szafarz M, Mika K, Dziubina A, Bednarski M, Muller C, Sapa J, Kieć-Konowicz K (2021) PSB 603 – a known selective adenosine A2B receptor antagonist–has anti-inflammatory activity in mice. Biomed Pharmacother 135:111164. 10.1016/j.biopha.2020.111164 Kuder KJ, Kotańska M, Szczepańska K, Mika K, Reiner-Link D, Stark H, Kieć-Konowicz K (2021) Discovery of Potential, Dual-Active Histamine H3 Receptor Ligands with Combined Antioxidant Properties. Molecules 26:2300. 10.3390/molecules26082300 https:// tools.thermofisher.com/content/sfs/manuals/PrestoBlue_Reagent_PIS_15Oct10.pdf https:// bioscience.lonza.com/lonza_bs/CH/en/download/product/asset/28213 Boissier PJ-R, Tardy J, Diverres J-C (1960) A new simple method to explore the tranquillizing action: the chimney test. Med Exp 3:81–84 Kubacka M, Mogilski S, Bednarski M, Nowiński L, Dudek M, Żmudzka E, Siwek A, Waszkielewicz MA, Marona H, Satała G, Bojarski A, Filipek B, Pytka K (2016) Antidepressant-like activity of aroxyalkyl derivatives of 2-methoxyphenyl piperazine and evidence for the involvement of serotonin receptor subtypes in their mechanism of action. Pharmacol Biochem Behav 141:28–41. 10.1016/j.pbb.2015.11.013 Jastrzębska-Więsek M, Kotańska M, Grzeszczak A, Jaromin A, Walczak M, Partyka A, Gdula-Argasińska J, Smolik M, Zagórska A (2022) The Antidepressant-like Activity, Effects on Recognition Memory Deficits, Bioavailability, and Safety after Chronic Administration of New Dual-Acting Small Compounds Targeting Neuropsychiatric Symptoms in Dementia. Int J Mol Sci 23:11452. 10.3390/ijms231911452 Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 01 Jul, 2024 Read the published version in Fitoterapia → Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4208153","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":287972069,"identity":"28799d5a-e8c9-487b-949f-22455d830f5a","order_by":0,"name":"Noemi Nicosia","email":"","orcid":"","institution":"University of Milano-Bicocca","correspondingAuthor":false,"prefix":"","firstName":"Noemi","middleName":"","lastName":"Nicosia","suffix":""},{"id":287972070,"identity":"61886333-2ef3-42d1-a81a-44234a2c3629","order_by":1,"name":"Inga Kwiecień","email":"","orcid":"","institution":"Jagiellonian University Medical College","correspondingAuthor":false,"prefix":"","firstName":"Inga","middleName":"","lastName":"Kwiecień","suffix":""},{"id":287972071,"identity":"2948e5d1-7caa-4bff-b3a5-6147bc9d8876","order_by":2,"name":"Marek Bednarski","email":"","orcid":"","institution":"Jagiellonian University Medical College","correspondingAuthor":false,"prefix":"","firstName":"Marek","middleName":"","lastName":"Bednarski","suffix":""},{"id":287972072,"identity":"7bfc8d0e-3b3e-4029-9ca9-73f1c139e546","order_by":3,"name":"Monika Głuch-Lutwin","email":"","orcid":"","institution":"Jagiellonian University Medical College","correspondingAuthor":false,"prefix":"","firstName":"Monika","middleName":"","lastName":"Głuch-Lutwin","suffix":""},{"id":287972073,"identity":"6ec2b099-5fb7-4372-95b9-82afbf885e54","order_by":4,"name":"Kamil Mika","email":"","orcid":"","institution":"Jagiellonian University Medical College","correspondingAuthor":false,"prefix":"","firstName":"Kamil","middleName":"","lastName":"Mika","suffix":""},{"id":287972074,"identity":"f42ffbf0-b941-42a5-aa0a-bcb211ec0f04","order_by":5,"name":"Rimma Hambaryan","email":"","orcid":"","institution":"Jagiellonian University Medical College","correspondingAuthor":false,"prefix":"","firstName":"Rimma","middleName":"","lastName":"Hambaryan","suffix":""},{"id":287972075,"identity":"808d8a81-2578-47bd-920d-fe57e4a6d884","order_by":6,"name":"Anthea Miller","email":"","orcid":"","institution":"University of Messina","correspondingAuthor":false,"prefix":"","firstName":"Anthea","middleName":"","lastName":"Miller","suffix":""},{"id":287972076,"identity":"a958eb00-a658-4155-a665-6981bd742b26","order_by":7,"name":"Alessio Alesci","email":"","orcid":"","institution":"University of Messina","correspondingAuthor":false,"prefix":"","firstName":"Alessio","middleName":"","lastName":"Alesci","suffix":""},{"id":287972077,"identity":"24fad48c-a483-46bb-9dea-82e755ebaab6","order_by":8,"name":"Eugenia R. Lauriano","email":"","orcid":"","institution":"University of Messina","correspondingAuthor":false,"prefix":"","firstName":"Eugenia","middleName":"R.","lastName":"Lauriano","suffix":""},{"id":287972078,"identity":"a42d01f6-c5a9-4518-9ce2-22657f524082","order_by":9,"name":"Paula Zammit","email":"","orcid":"","institution":"University of Malta","correspondingAuthor":false,"prefix":"","firstName":"Paula","middleName":"","lastName":"Zammit","suffix":""},{"id":287972079,"identity":"c7873df0-4eb1-420e-83f1-2b293666a09f","order_by":10,"name":"Salvatore Ragusa","email":"","orcid":"","institution":"PLANTA/Autonomous Center for Research, Documentation and Training","correspondingAuthor":false,"prefix":"","firstName":"Salvatore","middleName":"","lastName":"Ragusa","suffix":""},{"id":287972080,"identity":"4793163c-6e1b-4362-8a98-6c1efcdc6b2f","order_by":11,"name":"Ewa Trojan","email":"","orcid":"","institution":"Maj Institute of Pharmacology Polish Academy of Sciences","correspondingAuthor":false,"prefix":"","firstName":"Ewa","middleName":"","lastName":"Trojan","suffix":""},{"id":287972081,"identity":"2845c5e0-6bcb-43e2-9d4a-bd665a48689f","order_by":12,"name":"Jacek Sapa","email":"","orcid":"","institution":"Jagiellonian University Medical College","correspondingAuthor":false,"prefix":"","firstName":"Jacek","middleName":"","lastName":"Sapa","suffix":""},{"id":287972082,"identity":"11fcb2cf-4cbb-412a-af3f-1c174a830f6c","order_by":13,"name":"Natalizia Miceli","email":"","orcid":"","institution":"University of Messina","correspondingAuthor":false,"prefix":"","firstName":"Natalizia","middleName":"","lastName":"Miceli","suffix":""},{"id":287972083,"identity":"c7bfe14c-8bd1-4d0f-81ca-eb35bb835826","order_by":14,"name":"Magdalena Kotańska","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA80lEQVRIiWNgGAWjYJACCQYGZgaGA2yMDxh4gNwDQPyASC3MBnAtCURqYZMAcwlp0W0/fvHGDwbrxL7jbWnVPDIMcnw3Etge4NNidian2LKHIT1x5pljx27z8DAYS95IYDfAq+VATpoED8PhxA030ttAWoCMBDYJvFrOv0mT/APScv95WzFQSz1hLTfSj0lDbGE7xgzUkmBAWMsbZmsZg3TjmWfSkiXn8EgYzjzzsB2/X86nP7z5psJatu/4McMPb3ts5PmOJx978AGPFgYGHgMGBgMom7EHFDWMbXg1MDCwP0Di/ACTbAS0jIJRMApGwQgDALLoUucvkbB4AAAAAElFTkSuQmCC","orcid":"","institution":"Jagiellonian University Medical College","correspondingAuthor":true,"prefix":"","firstName":"Magdalena","middleName":"","lastName":"Kotańska","suffix":""}],"badges":[],"createdAt":"2024-04-02 16:59:35","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4208153/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4208153/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1016/j.fitote.2024.106138","type":"published","date":"2024-07-01T12:33:13+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":54453808,"identity":"a9668f9b-1dfb-41c4-8eb7-6849525cc753","added_by":"auto","created_at":"2024-04-10 18:40:51","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":43569,"visible":true,"origin":"","legend":"\u003cp\u003e(\u003cstrong\u003ea\u003c/strong\u003e) Vicenin-2 structure, (\u003cstrong\u003eb\u003c/strong\u003e) quercetin structure.\u003c/p\u003e","description":"","filename":"F1.png","url":"https://assets-eu.researchsquare.com/files/rs-4208153/v1/c745d5d0b6a01e165d8026e3.png"},{"id":54453804,"identity":"3fd43f37-a9b7-4fc3-bf4a-326ca97a196f","added_by":"auto","created_at":"2024-04-10 18:40:51","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":10621,"visible":true,"origin":"","legend":"\u003cp\u003eStandard absorbance curve of Fe\u003csup\u003e2+\u003c/sup\u003e.\u003c/p\u003e","description":"","filename":"Picture1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4208153/v1/2a07ff104deb6fe04dd9ee06.jpg"},{"id":54453806,"identity":"e5cc0ab6-b557-4f99-bddc-e2c2ca90c521","added_by":"auto","created_at":"2024-04-10 18:40:51","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":36114,"visible":true,"origin":"","legend":"\u003cp\u003eInfluence of different concentrations of IT leaves extract on BSA glycation after 3 weeks of incubation. Mean ± SD from three separate duplicated experiments, n=3. To calculate the significance of differences between the groups one-way ANOVA followed by Tukey’s post hoc test was used. * Significant difference vs BSA+PBS group, ^ significant difference vs BSA+Fructose group. Significance level: ^ p \u0026lt;0.05, ***, ^^^ p\u0026lt;0.001.\u003c/p\u003e","description":"","filename":"Picture2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4208153/v1/9a1d25cde10ea62e0d5f5922.jpg"},{"id":54453803,"identity":"585a0599-19e5-44b8-87b6-5cb9605f4a2c","added_by":"auto","created_at":"2024-04-10 18:40:51","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":30122,"visible":true,"origin":"","legend":"\u003cp\u003eInfluence of different concentrations of IT leaves extract on alpha-glucosidase activity. Mean ± SD from three separate duplicated experiments, n=3.\u003c/p\u003e","description":"","filename":"Picture3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4208153/v1/fdf5459e35b575ba13d2c804.jpg"},{"id":54453802,"identity":"29aecb81-f74a-4d81-a608-043748deb5d5","added_by":"auto","created_at":"2024-04-10 18:40:51","extension":"jpg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":32480,"visible":true,"origin":"","legend":"\u003cp\u003eInfluence of different concentrations of IT leaves extract on acetylcholinesterase activity. Mean ± SD from three separate duplicated experiments, n=3.\u003c/p\u003e","description":"","filename":"Picture4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4208153/v1/fd52987536bfc92be4d34b65.jpg"},{"id":54453810,"identity":"d90df048-963b-4ca2-86cc-1cf55c59d602","added_by":"auto","created_at":"2024-04-10 18:40:52","extension":"jpg","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":24448,"visible":true,"origin":"","legend":"\u003cp\u003eCytotoxic effect of different concentrations of IT leaves extract on HT-22 cells after 24 hours of incubation: the percentage of live cells \u003cem\u003evs \u003c/em\u003evehicle sample - Presto Blue assay (\u003cstrong\u003ea\u003c/strong\u003e), the percentage of damaged cells \u003cem\u003evs\u003c/em\u003e lysis sample - ToxiLight assay (\u003cstrong\u003eb\u003c/strong\u003e). Mean ± SD from two separate duplicated experiments, n=2.\u003c/p\u003e","description":"","filename":"Picture5.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4208153/v1/a7701513b44ad95ae2237bb9.jpg"},{"id":54453811,"identity":"c06b93c9-7c08-45cb-810b-8f03a3775fa4","added_by":"auto","created_at":"2024-04-10 18:40:53","extension":"jpg","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":18001,"visible":true,"origin":"","legend":"\u003cp\u003eAntioxidant effect of IT leaves extract (\u003cstrong\u003ea\u003c/strong\u003e) or ascorbic acid (\u003cstrong\u003eb\u003c/strong\u003e) in FRAP assay. The results are presented as the mean ± SD from two separate duplicated experiments.\u003c/p\u003e","description":"","filename":"Picture6.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4208153/v1/058a3b59d8ffe01b44f5f860.jpg"},{"id":54453807,"identity":"58587083-a5e0-44c5-ae88-f47e578acf6c","added_by":"auto","created_at":"2024-04-10 18:40:51","extension":"jpg","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":13684,"visible":true,"origin":"","legend":"\u003cp\u003eChanges in mice body mass after administration of IT leaves extract. The results are presented as the mean of the measurements ± Δ/2, where Δ is the width of the 95% confidence interval (CI). One-way ANOVA followed by Dunnett’s post hoc test was used to calculate the significance of differences between the groups; n = 8.\u003c/p\u003e","description":"","filename":"Picture7.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4208153/v1/1344baf783875f62dd958262.jpg"},{"id":54453809,"identity":"57122288-40fb-42d1-b3d1-3f67e4ce8e67","added_by":"auto","created_at":"2024-04-10 18:40:52","extension":"jpg","order_by":9,"title":"Figure 9","display":"","copyAsset":false,"role":"figure","size":16438,"visible":true,"origin":"","legend":"\u003cp\u003eLocomotor activity of mice after administration of IT leaves extract. The results are presented as the mean of the measurements ± Δ/2, where Δ is the width of the 95% confidence interval (CI). One-way ANOVA followed by Dunnett’s post hoc test was used to calculate the significance of differences between the groups; n = 8. * Significant difference \u003cem\u003evs\u003c/em\u003e control group, significance level: *p \u0026lt;0.05\u003c/p\u003e","description":"","filename":"Picture8.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4208153/v1/c63d96ca53d7853874d1095a.jpg"},{"id":54453805,"identity":"65bb307f-ae56-491d-b0a1-6e72cd6d783f","added_by":"auto","created_at":"2024-04-10 18:40:51","extension":"jpg","order_by":10,"title":"Figure 10","display":"","copyAsset":false,"role":"figure","size":15127,"visible":true,"origin":"","legend":"\u003cp\u003eEscape time from chimney after administration of IT leaves extract. The results are presented as the mean of the measurements ± Δ/2, where Δ is the width of the 95% confidence interval (CI). One-way ANOVA followed by Dunnett’s post hoc test was used to calculate the significance of differences between the groups; n = 6. * Significant difference vs control group, significance level: *p \u0026lt;0.05\u003c/p\u003e","description":"","filename":"Picture9.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4208153/v1/029c9c22df8657eda7ecc67e.jpg"},{"id":54453801,"identity":"a3c77bc5-9107-47e6-ae8b-9045ecf0b9ad","added_by":"auto","created_at":"2024-04-10 18:40:49","extension":"jpg","order_by":11,"title":"Figure 11","display":"","copyAsset":false,"role":"figure","size":32936,"visible":true,"origin":"","legend":"\u003cp\u003ePlasma enzyme activity: alanine aminotransferase (AlaT, \u003cstrong\u003ea\u003c/strong\u003e), aspartate aminotransferase (AspaT, \u003cstrong\u003eb\u003c/strong\u003e), gamma-glutamyl transpeptidase (gGT, \u003cstrong\u003ec\u003c/strong\u003e) and alkaline phosphatase (AP, \u003cstrong\u003ed\u003c/strong\u003e) after administration of leaves extract. The results are presented as the mean of the measurements ± Δ/2, where Δ is the width of the 95% confidence interval (CI). One-way ANOVA followed by Dunnett’s post hoc test was used to calculate the significance of differences between the groups; n = 7-8. * Significant difference vs control group, significance level: *p \u0026lt;0.05\u003c/p\u003e","description":"","filename":"Picture10.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4208153/v1/836fbeddfe4367b1b986df96.jpg"},{"id":54453812,"identity":"21b831ab-cfc7-425e-9c93-760b438dd133","added_by":"auto","created_at":"2024-04-10 18:40:53","extension":"jpg","order_by":12,"title":"Figure 12","display":"","copyAsset":false,"role":"figure","size":12319,"visible":true,"origin":"","legend":"\u003cp\u003eTotal plasma antioxidant power 1 hour after administration of IT leaves extract to mice. The results are presented as the mean of the measurements ± Δ/2, where Δ is the width of the 95% confidence interval (CI). One-way ANOVA followed by Dunnett’s post hoc test was used to calculate the significance of differences between the groups; n = 6-8. * Significant difference vs control group, significance level: ** p\u0026lt;0.001\u003c/p\u003e","description":"","filename":"Picture11.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4208153/v1/c704faede8e4fd613990537a.jpg"},{"id":61162407,"identity":"e11fdb3e-d18c-4f4f-943f-cd7c129b1f7b","added_by":"auto","created_at":"2024-07-26 12:33:23","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1251294,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4208153/v1/86d1cfcd-bf8c-4dc9-88e4-4d7ab44a3ab9.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Anti-diabetes and neuroprotection potential and primary safety studies of Isatis tinctoria L. hydroalcoholic leaf extract","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eDiabetes mellitus (DM) is an endocrine disease characterized by dysfunctional metabolism of lipids and carbohydrates by insulin, a pancreatic hormone, leading to an increase in blood glucose levels [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. DM is a global health crisis that deeply affects the personal, social, and physical well-being of the population. Current therapeutic strategies for glycaemic control include insulin and its analogues, sulphonylureas, biguanides, thiazolidinediones, and α-glucosidase inhibitors [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. Glycation inhibitors are a potential drug class for the management of disorders caused by hyperglycemia, however, to date, none of the tested compounds (aminogluanidine was the closest to success) have undergone clinical trials [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eEmerging evidence highlights the strong link between DM and Alzheimer\u0026rsquo;s disease (AD) and is lately often referred to as \"type 3 diabetes\", because of the crucial role of insulin in cognitive function and neurodegenerative processes involving memory elaboration and neuronal integrity [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. The connection between the two pathologies is further complicated by inflammation, oxidative stress, and glycation, which are exacerbated in DM, in addition to significantly contributing to the development of AD [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e].\u003c/p\u003e \u003cp\u003ePlant-derived drugs with antioxidant, anti-inflammatory and antibacterial properties have gained attention due to their numerous advantages, such as low toxicity, mild side effects, as well as multiple pharmacological targets [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Therefore, the search for natural products or phytochemicals is growing, with the possibility that they may become acceptable alternatives or complementary agents to existing pharmacological treatment [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn view of this, \u003cem\u003eIsatis tinctoria\u003c/em\u003e L. (IT) is a plant of great interest as it exhibits various beneficial properties closely related to its phytochemical profile. It is well known for its use as a Chinese herb in the treatment of inflammatory diseases, viral and bacterial infections in Traditional Chinese Medicine [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. \u003cem\u003eIsatis tinctoria\u003c/em\u003e was recognized as a pharmacopoeial plant and introduced into official European phytomedicine in 2011 [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. In the pharmacopoeial monograph, \u003cem\u003eIsatis indigotica\u003c/em\u003e was listed as another name for \u003cem\u003eIsatis tinctoria\u003c/em\u003e. This record was maintained until the current 10th edition of the European Pharmacopeia [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. When describing \u003cem\u003eIsatidis radix\u003c/em\u003e (BănL\u0026aacute;nGēn) and \u003cem\u003eIsatidis folium\u003c/em\u003e (D\u0026agrave;QīngY\u0026egrave;), many of the researchers following the Chinese pharmacopoeia claim that these raw materials originate from \u003cem\u003eI. indigotica\u003c/em\u003e [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Nevertheless, some new works consider them to be two different species [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Despite considering them as separate species, the European Pharmacopeia deems them to be equivalent for the purposes of obtaining the raw material. The European monograph concerns \u003cem\u003eIsatidis radix\u003c/em\u003e. However, \u003cem\u003eIsatidis folium\u003c/em\u003e is not included, which necessitates research into the biological activity of the leaf extract in animal models and into the safety of its use.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003eRecently, the increasing demand for the use of IT for its medicinal properties has driven a renewed interest in the promising biological activities ascribed to its bioactive compounds, which include alkaloids, phenolic compounds, and glucosinolates [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. As a result, in the last decade, extracts obtained from IT leaves and roots have been the subject of numerous phytochemical studies and investigations into their therapeutic potential in animal and human diseases [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Studies have mainly focused on analysing the lipophilic extract of IT and evaluating its strong anticancer and anti-inflammatory properties in various animal models [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Isolated compounds such as the alkaloids tryptanthrin, indolinone, and indirubin have been widely examined for their beneficial health effects [\u003cspan additionalcitationids=\"CR18 CR19\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e].\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003eHowever, to date, few investigations have been carried out on the biological activity of the polar constituents of this species [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan additionalcitationids=\"CR22 CR23\" citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. The phenolic compounds of the hydroalcoholic extract (MeOH 70) of IT leaves were first characterized by Taviano et al., and next Miceli et al., revealed a strong correlation between antioxidant activity and flavonoids and phenolic acids [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. Among the flavonoids identified in the said extract, vicenin-2 was the most abundant flavone, followed by isovitexin and apigenin glucosides, whereas quercetin was the most abundant flavonol. The polar extract showed good radical scavenging and ferrous ion chelating activity, as well as moderate reduction power, ascribed to the high concentration of flavonoids [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. Interestingly, vicenin-2, also known as 6,8-di-C-glucoside of apigenin, has been reported to possess a wide variety of pharmacological activity including anti-cancer, anti-inflammatory, antioxidant, and hepatoprotective properties [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. An \u003cem\u003ein vivo\u003c/em\u003e study, conducted in a carrageen-induced rat paw oedema model, demonstrated that vicenin-2 blocks the production of inflammatory mediators such as tumor necrosis factor-α (TNF-α) and nitric oxide (NO) through the inhibition of nuclear factor-kB (NF-kB) [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. In addition, interesting findings come from a study focusing on the antidiabetic potential of vicenin-2 as a result of the strong inhibition of α-glucosidase, aldose reductase, and protein tyrosine phosphatase 1B. These three enzymes have become important therapeutic targets in the treatment of diabetes mellitus [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. Furthermore, a notably increasing number of studies highlight the therapeutic potential of apigenin, a natural flavone, in the management of neurodegenerative disorders. A recent experiment conducted in a rat model of AD, revealed the ability of apigenin to inhibit glycogen synthase kinase-3 beta, a molecule that plays a key role in the generation of amyloid beta plaques and neurofibrillary tangles, leading to neuroprotective effects [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eLittle information is available on the historical use of IT in European countries since its introduction to Europe from China and Japan in ancient times is only described by Hamburger [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. The raw material used in the experiments in this work comes from natural sites in Italy and has been identified as \u003cem\u003eIsatis tinctoria\u003c/em\u003e. In view of the absence of information on the action and activity of the European raw material, such studies are most needed and recommended.\u003c/p\u003e\u003cp\u003eIn our previous article, we showed that a single administration of IT hydroalcoholic leaf extract reverses anxiety-like behavior caused by the acute restraint stress paradigm through a mechanism partially dependent on the modulation of neuroinflammation, oxidative stress, and NO reduction [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. In this manuscript, taking into account that IT hydroalcoholic leaf extract has high concentrations of vicenin-2 (6,8-di-C-glucoside of apigenin) or quercetin [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e], which reduce protein glycation [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e] and significantly inhibit the activity of enzymes involved in the breakdown of complex carbohydrates in the digestive tract, such as amylase [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e] or alpha-glucosidase [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e], we determined the impact of the tested extract on protein glycation and on alpha-glucosidase activity. We compared the effect of IT extract to the effect of its main active compounds, i.e., vicenin-2 and quercetin (Fig.\u0026nbsp;1 shows the structures of these compounds). Moreover, we examined the effect of the IT extract on acetylcholinesterase activity. We also assessed the \u003cem\u003ein vitro\u003c/em\u003e and \u003cem\u003ein vivo\u003c/em\u003e safety of IT hydroalcoholic leaf extract. Confirmation of safety is extremely important in the early-stage development of a therapeutic agent. Products that have significant side effects are excluded from further research, saving time, money, and lives of animals. Such screening using safety assays is necessary to select the appropriate doses for future testing in specific indications and to clearly confirm the potential for \u003cem\u003ein vivo\u003c/em\u003e use.\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e "},{"header":"2. Materials and Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1. Plant material\u003c/h2\u003e \u003cp\u003e\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003eThe leaves were picked from IT growing in the wild around Acireale (Catania, Sicily, Italy). The dried plant material was extracted according to the procedure reported by Taviano et al. [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. Finally, the hydroalcoholic extract (MeOH 70%) was evaporated to dryness in vacuum. The yield, referred to as 100g of dried plant material, was 24.32%. Prof. Salvatore Ragusa confirmed the taxonomic identity of the plant material. The specimens are deposited in the Herbarium of the Department of Scienze della Salute, University \u0026ldquo;Magna Graecia\u0026rdquo; of Catanzaro (Italy), under accession number no. 327/11. Phytochemical analysis of the extract was previously performed by HPLC-PDA-ESI-MS\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2. In vitro protein glycation\u003c/h2\u003e \u003cdiv id=\"Sec5\" class=\"Section3\"\u003e \u003ch2\u003e2.2.1. Preparation of samples of glycated BSA\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe formation of glycated BSA was determined using the modified method of Vinson and Howard, 1996 [\u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e], with minor modifications. In brief, BSA (10 mg/mL) in 100 mM sodium phosphate buffer (pH 7.4) was incubated with fructose solution (0.5mM), 0.02% sodium azide, (used to prevent bacterial growth), and the tested solutions. Quercetin was used as the reference compound. Only BSA in the same buffer without fructose was a blank. The reaction mixtures were incubated for twenty one days (at 37\u0026deg;C) and were then assayed to determine the quantity of advanced glycation end products.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section3\"\u003e \u003ch2\u003e2.2.2. Formation of advanced glycation end products\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe fluorescence intensity of the reaction products was determined using spectrofluorometric detector POLAR star Omega (BMG Labtech, Germany), wavelengths of excitation and emission: 340 nm, 440 nm. The results are presented as fluorescence intensity and are expressed as advanced glycation end products (AGEs) units: 1U\u0026thinsp;=\u0026thinsp;fluorescence of 0.5M fructose solution.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e2.3. Alpha-glucosidase inhibition assay\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe effect of the tested extract on alpha-glucosidase activity was measured using a previously described method [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e], with minor modifications. In brief, 100 \u0026micro;L of tested solution in 100 mM phosphate buffer (pH 6.8), 20 \u0026micro;L 0.2 U/mL alpha-glucosidase in 100 mM phosphate buffer (pH 6.8), and 100 \u0026micro;L of 100 mM phosphate buffer (pH 6.8) were added to a plate. The plate was incubated at 37\u0026deg;C for 15 min. The enzymatic reaction was initiated by the addition of 50 \u0026micro;L of 2.5 mM p-nitrophenyl alpha-D-glucopyranoside (p-NPG, Merck, Germany). The plate was incubated at 37\u0026deg;C for 20 min, and the reaction was stopped by adding 50 \u0026micro;L of 0.1 mol/L sodium carbonate solution.. The absorbance (λ\u0026thinsp;=\u0026thinsp;405 nm) was measured using a plate reader (ThermoFisher Scientific, USA). Vicenin-2, quercetin and acarbose were used as reference compounds. The inhibition percentage was calculated using the formula:\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Equa\" class=\"Equation\"\u003e \u003cdiv format=\"TEX\" class=\"mathdisplay\" id=\"FileID_Equa\" name=\"EquationSource\"\u003e\n$$I \\left[\\%\\right]= \\frac{Ac-As}{Ac} \\times 100\\%$$\u003c/div\u003e \u003c/div\u003e,\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003ewhere Ac is the absorbance of control, and As is absorbance of the sample.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e2.4. Acetylcholineesterase inhibition assay\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe effect of the tested extract on acetylcholineesterase \u003cem\u003e(\u003c/em\u003eAchE) activity was measured as described by [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e], with minor modifications. The reaction mixture contained: 60 \u0026micro;L of 100 mM sodium phosphate buffer (pH 8.2), 50 \u0026micro;L of the tested sample solution, 50 \u0026micro;L of 5,5\u0026prime;-dithiobis(2-nitrobenzoic acid) (6mM, Merck, Germany) and 20 \u0026micro;L of 0.5 U/mL AchE solution (Merck, Germany). It was incubated at room temperature (10 min). The reaction was initiated by the addition of 20 \u0026micro;L of acetylthiocholine iodide (25 mM, Merck, Germany). The absorbance was measured at λ\u0026thinsp;=\u0026thinsp;412 nm after 5 min, using a plate reader (ThermoFisher Scientific, USA). The inhibition percentage was calculated using the formula:\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Equb\" class=\"Equation\"\u003e \u003cdiv format=\"TEX\" class=\"mathdisplay\" id=\"FileID_Equb\" name=\"EquationSource\"\u003e\n$$I \\left[\\%\\right]=100-\\left( \\frac{As*100}{Ac} \\right)$$\u003c/div\u003e \u003c/div\u003e,\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003ewhere Ac is the absorbance of the control, and As is absorbance of the sample.\u003c/p\u003e \u003cp\u003eTactine, vicenin-2, and quercetin (Merck, Germany) were used as reference compounds.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003e\u003cem\u003e2.5. Reduction assay (ferric reducing antioxidant power, FRAP) \u0026ndash; in vitro\u003c/em\u003e\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe total antioxidant activity of the IT extract was determined by spectrophotometric determination of the reduced iron concentration. The assay was performed as described by Benzie and Strain [\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e] with some modifications [\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e, \u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e]. The assay was carried out as follows 10 \u0026micro;L of the extract or solvent and 300 \u0026micro;L of the reagent were added to the following composition: ten parts of 0.3 M sodium acetate buffer (pH 3.7), one part of 2,4,6-tris(2-pyridyl)-s-triazine solution (0.01 M, Merck, Germany) and one part of FeCl\u003csub\u003e3\u003c/sub\u003e \u0026times; 6 H\u003csub\u003e2\u003c/sub\u003eO solution (0.02 M). The absorbance was measured after 10 min of incubation (room temperature, 593 nm). Deionized water with FRAP solution was used as a blank. Ascorbic acid was used as the reference compound. The results for the tested extract were presented as the amount of reduced iron (III) ions. FeSO\u003csub\u003e4\u003c/sub\u003e \u0026times; 7H\u003csub\u003e2\u003c/sub\u003eO salt was used for the construction of a standard curve (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003e2.6. Cytotoxicity assay \u0026ndash; in vitro\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe extract was tested at six concentrations ranging from 25 to 1 mg/mL using the mouse hippocampal neuronal cell line (HT-22).\u003c/p\u003e \u003cp\u003eHT-22 were cultured in Dulbecco's modified Eagle's Medium-high glucose (DMEM, Glutamx, ThermoFisher Scientific, USA) supplemented with 10% heat inactivated fetal bovine serum (ThermoFisher Scientific, USA), 100 \u0026micro;g/mL streptomycin (Merck, Germany), and 100 IU/mL penicillin (Sigma Aldrich). The cells were placed in a 96-well culture plate (2x10\u003csup\u003e4\u003c/sup\u003e cells per well, Falcon) and were grown for 24 hours in the sterile condition (37\u0026deg;C, 5% CO\u003csub\u003e2\u003c/sub\u003e). Subsequently, different concentrations of the extract were added and incubated for 24 hours. Cell viability was determined using both the Presto Blue and the ToxiLight assays.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cdiv id=\"Sec11\" class=\"Section3\"\u003e \u003ch2\u003e2.6.1. Presto Blue assay\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe Presto Blue reagent (ThermoFisher Scientific, USA) was used to evaluation of cell viability [\u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e75\u003c/span\u003e]. After 24 hours of incubation with the extract, 10 \u0026micro;l of PrestoBlue reagent was added and incubated for 15 minutes at 37\u0026deg;C. The fluorescence intensity (wavelengths of excitation and emission: 340 nm, 440 nm) was measured in a plate reader (POLARstar Omega, BMG Labtech). The results were provided as the percentage of live cells with respect to the vehicle sample.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section3\"\u003e \u003ch2\u003e2.6.2. ToxiLight assay\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe ToxiLight reagent (Lonza, Switzerland), which measures membrane damage, was used to evaluation of cell viability [\u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e]. It quantitatively measures the release of adenylate kinase from the membrane of damaged cells. After 24 hours of treatment, the supernatant was transferred to a new plate and the adenylate kinase detection reagent was added. Luminescence was measured after 5 minutes of incubation in a plate reader (POLARstar Omega, BMG Labtech). The results were provided as the percentage of damaged/lysed cells.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003e2.7. Animals\u003c/h2\u003e \u003cp\u003e\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e All animal care and experimental procedures were carried out in accordance with the European Union and Polish legislation acts concerning animal experimentation and were approved by the Local Ethics Committee of Jagiellonian University of Cracow, Poland (Permissions No: 473/2020, date: 16.12.2020; No: 545B/2021, date: 21.07.2021).\u003c/p\u003e\u003cp\u003eThe animals were obtained from the Animal House of the Jagiellonian University Pharmaceutical Faculty. Six-week-old male Albino Swiss mice, CD-1, weighing 20\u0026ndash;22 g, were used. They were kept in environmentally controlled rooms, in standard cages lit by artificial light for 12 hours per day. The animals had free access to food and water, except for during the acute experiment. The randomly established experimental groups consisted of 8 mice.\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003e2.8. Extract dosage and administration schedule\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe extract was administered intraperitoneally (i.p.) to mice, at the following doses: 50 mg/kg, 100 mg/kg, or 500 mg/kg b.w. These are the same doses of \u003cem\u003eIsatis tinctoria\u003c/em\u003e leaf extract described in our previous manuscript [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. The vehicle (1% Tween 80; Sigma-Aldrich, Poland) was administered i.p. at a volume of 10 mL/kg. Thirty minutes after the first administration, the chimney and Rotarod tests were performed. Seven days later, 30 minutes after the second administration, locomotor activity was measured. Exactly one hour after administration of the extract, plasma was collected for biochemical testing.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003e2.9. Chimney test\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe mice were trained before the test and only those animals that could get out of the chimney in less than 1 minute were used in the experimental stage. The selected mice were placed in a horizontal tube (length 25cm, diameter 2.5cm), which was next set up vertical, in such a way that the mice could only exit by climbing backwards until they reached the other end. Motor impairment was established to be the inability of the mice to exit the tube within 60 seconds. The number of animals unable to climb backwards within 60 seconds was recorded and was expressed as the % of animals that could not climb out [\u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e77\u003c/span\u003e]. The mice were injected with the extract 30 minutes prior to the chimney test.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003e2.10. Rotarod test\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eIn brief, the mice were trained on the Rotarod apparatus (May Commat RR0711, Turkey; rod diameter: 2cm) prior to the experiment. During each training session, the mice were placed on the rotating rod (10 rpm, constant speed) twice for 3 minutes. The experiment was carried out 24 hours after the last training session. On the day of the test, the mice were injected with the extract, and 30 minutes after administration, tested on the chimney test, followed by the Rotarod test (10 rpm, constant speed). Motor impairment was regarded as the inability to remain on the rotating rod for 60 seconds and was expressed as the percentage of animals that fell off the rotating rod [\u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003e2.11. Change of body weight after administration of the tested extract\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eMice were weighed prior to test extract administration and 24 hours after administration, on a weighing scale suitable for small animals (K-PZ Waagen, Germany).\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003e\u003cem\u003e2.12. Locomotor activity test after single administration of test extract\u003c/em\u003e\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eLocomotor activity was individually recorded for each animal using specifically designed activity cages made of clear Perspex (40 cm \u0026times; 40 cm \u0026times; 31 cm, Activity Cage 7441, Ugo Basile, Italy). The cages were fitted with I.R. horizontal beam emitters connected to a counter, which records the light-beam interruptions. Prepared suspensions of the extract were administered as i.p. injections 30 minutes before testing. The control animals received i.p. injections of vehicles. Each mouse was placed in the cage for a 30-minute habituation period (immediately after administration). Afterwards, the number of photo beam interruptions was measured for 5 minutes, which is the same observation period used in other tests.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003e2.13. Plasma collection\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eAt the end of the experiment, 60 minutes after IT or vehicle administration and 20 minutes after ip administration of heparin (2500 units/mouse; Polfa Warszawa S.A., Poland), blood was collected after decapitation. It was centrifuged at 600 x g for 15 min (4\u0026deg;C) in order to obtain plasma. It was frozen in liquid nitrogen and placed in a freezer (-80\u0026deg;C) until biochemical assays were performed.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003e2.14. Biochemical analysis\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eTo determine alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (γGTP), alanine aminotransferase (AlaT), and asparagine aminotransferase (AspaT) activity in plasma, a standard enzyme spectrophotometric tests (Biomaxima S.A., Poland) were used. Absorbance was measured at a wavelength of 405 nm (ALP, γGTP) or 340 nm (AlaT, AspaT).\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec21\" class=\"Section2\"\u003e \u003ch2\u003e2.15. The Ferric Reducing Ability of Plasma (FRAP) - a measure of \u0026ldquo;Antioxidant Power\u0026rdquo;\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe assay was performed as described by Benzie and Strain [\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e] with some modifications [\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e]. The FRAP working solution was prepared before the start of the analysis, using 0.3 mol of acetate buffer (pH 3.6), 0.01 mol of 2,4,6-tripyridyl-s-triazine (Merck, Germany) in 0.04 mol of HCl (POCh, Poland) and 0.02 M FeCl\u003csub\u003e3\u003c/sub\u003e\u0026times;6H\u003csub\u003e2\u003c/sub\u003eO in water (iron III) (Chempur, Poland), which were mixed in a volumetric ratio of 10:1:1 and protected from light. Subsequently, 20 \u0026micro;L of the plasma sample tested, brain homogenate, or FeSO\u003csub\u003e4\u003c/sub\u003e\u0026times;7H\u003csub\u003e2\u003c/sub\u003eO solution was mixed with 180 \u0026micro;L of the FRAP working solution. The mixtures obtained were incubated at 37\u0026deg;C for 30 minutes and absorbance was measured at 593 nm. FeSO\u003csub\u003e4\u003c/sub\u003e\u0026times;7H\u003csub\u003e2\u003c/sub\u003eO (Chempur, Poland) was used to create a standard curve (100\u0026ndash;1000 \u0026micro;mol/L). Deionized water containing FRAP solution was used as the blank.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec22\" class=\"Section2\"\u003e \u003ch2\u003e2.16. Statistical analysis\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eStatistical calculations were performed using GraphPad Prism 9 software (GraphPad Software, USA). Results are expressed as mean\u0026thinsp;+\u0026thinsp;standard deviation (SD) or mean\u0026thinsp;+\u0026thinsp;Δ/2, where Δ is a width of the 95% confidence interval (CI), n\u0026thinsp;=\u0026thinsp;6\u0026ndash;8. Statistical significance was calculated using one-way ANOVA, Dunnet or Tuckey post hoc test. Differences were considered statistically significant at: *p\u0026thinsp;\u0026le;\u0026thinsp;0.05, **p\u0026thinsp;\u0026le;\u0026thinsp;0.01, ***p\u0026thinsp;\u0026le;\u0026thinsp;0.001.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"3. Results","content":"\u003cdiv id=\"Sec24\" class=\"Section2\"\u003e \u003ch2\u003e3.1. Influence on bovine serum albumin (BSA) glycation\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eIT extract caused a reduction in the formation of advanced glycation products (AGEs). Incubation of the extract at concentrations 25 mg/mL, 20 mg/mL and 15 mg/mL with BSA and 0.5M fructose solution for three weeks significantly reduced the formation AGEs compared to the control sample, i.e. BSA and 0.5M fructose. The results are shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e3\u003c/span\u003e.\u003c/p\u003e \u003cp\u003eThe active compound in the IT extract, vicenin-2, also significantly inhibited the glycation of BSA at concentrations 10\u003csup\u003e\u0026minus;\u0026thinsp;5\u003c/sup\u003e and 10\u003csup\u003e-6\u003c/sup\u003eM. Quercetin, the reference compound used, reduced the formation of AGEs to a comparable extent as vicenin-2.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec25\" class=\"Section2\"\u003e \u003ch2\u003e3.2. Influence on alpha-glucosidase activity\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eIT extract inhibited α-glucosidase activity in a concentration-dependent manner. The results are shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e4\u003c/span\u003e. The highest concentration of IT extract tested, 1 mg/mL, inhibited the activity of the enzyme by approximately 50%, and a concentration ten times lower inhibited it by less than 10%. This effect was stronger than that of the selected compounds - vicenin-2 and quercetin.\u003c/p\u003e \u003cp\u003eThe active compounds from the IT extract, vicenin-2 and quercetin, also inhibited α-glucosidase activity at concentrations 10\u003csup\u003e\u0026minus;\u0026thinsp;5\u003c/sup\u003e, 10\u003csup\u003e\u0026minus;\u0026thinsp;6\u003c/sup\u003e and 10\u003csup\u003e\u0026minus;\u0026thinsp;7\u003c/sup\u003e M. However, the effect was only about 15% at the highest concentration used (10\u003csup\u003e\u0026minus;\u0026thinsp;5\u003c/sup\u003e) and was half as weak compared to the inhibition at the lowest concentration of acarbose used (10\u003csup\u003e\u0026minus;\u0026thinsp;7\u003c/sup\u003e). Additionally, inhibition by the IT extract was about 5.5 times weaker in comparison to the inhibition at the same concentration by acarbose (10\u003csup\u003e\u0026minus;\u0026thinsp;5\u003c/sup\u003e). Acarbose, the reference compound used, inhibited α-glucosidase activity in a concentration-dependent manner.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec26\" class=\"Section2\"\u003e \u003ch2\u003e3.3. Influence on acetylcholinesterase (AchE) activity\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eIT extract inhibited acetylcholinesterase activity at all the tested concentrations. The results are shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e5\u003c/span\u003e. At the highest concentration, 1 mg/mL, the IT extract inhibited the activity of the enzyme by approximately 25%, at half the maximum concentration it inhibited the activity of AchE by about 20%, and at lower concentrations, 0.25 mg/mL and 0.1 mg/mL, inhibition was below 5%. The inhibitory activity determined for the two highest concentrations of IT extract was similar to that of the selected compounds - vicenin-2 and quercetin, at concentrations 10\u003csup\u003e\u0026minus;\u0026thinsp;4\u003c/sup\u003e to 10\u003csup\u003e\u0026minus;\u0026thinsp;6\u003c/sup\u003e, but lower than inhibitory activity of tacrine.\u003c/p\u003e \u003cp\u003eThe active compounds from the IT extract, vicenin-2 and quercetin, inhibited AchE activity at concentrations 10\u003csup\u003e\u0026minus;\u0026thinsp;4\u003c/sup\u003e, 10\u003csup\u003e\u0026minus;\u0026thinsp;5\u003c/sup\u003e and 10\u003csup\u003e\u0026minus;\u0026thinsp;6\u003c/sup\u003e M. However, this effect was only about 30\u0026thinsp;\u0026minus;\u0026thinsp;20% at the highest concentration used (10\u003csup\u003e\u0026minus;\u0026thinsp;4\u003c/sup\u003e) and was weak compared to activity of tacrine at the same concentration.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003eTacrine, the reference compound used, inhibited AchE activity in a concentration-dependent manner.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec27\" class=\"Section2\"\u003e \u003ch2\u003e3.4. Toxicity Study and Antioxidant Assays\u003c/h2\u003e \u003cdiv id=\"Sec28\" class=\"Section3\"\u003e \u003ch2\u003e3.4.1. Cytotoxicity\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe extract was not cytotoxic at all the concentrations tested. Cell viability was determined using the Presto Blue assay, the number of cells in the control (vehicle, water) being 100% live cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e6\u003c/span\u003ea) and in the ToxiLight assay, 100% damaged cells being present in the lysis sample (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e6\u003c/span\u003eb).\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec29\" class=\"Section3\"\u003e \u003ch2\u003e3.4.2. Reduction activity\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eIn the FRAP assay, IT extract caused a concentration-dependent reduction of iron (III) ions. 1 gram of extract reduced 60 mmol Fe\u003csup\u003e3+\u003c/sup\u003e to 140 mmol (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e7\u003c/span\u003ea).\u003c/p\u003e \u003cp\u003eAscorbic acid was used as the reference compound. An increase in absorbance, proportional to the concentration of reduced iron (0.1\u0026ndash;1 mM) was determined, indicating an increase in total antioxidant activity. The maximum activity of ascorbic acid occurred a concentration of 1 mM (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e7\u003c/span\u003eb).\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec30\" class=\"Section2\"\u003e \u003ch2\u003e3.5 Influence on the body mass of mice\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe tested extracts did not have a significant effect on the body mass of mice during a 24-hour period, after one intraperitoneal administration. The results are shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e8\u003c/span\u003e.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec31\" class=\"Section2\"\u003e \u003ch2\u003e3.6 Influence on the locomotor activity of mice\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe locomotor activity of mice decreased significantly after administration of 50 mg/kg b.w. (F(3.28)\u0026thinsp;=\u0026thinsp;3.948, p\u0026thinsp;=\u0026thinsp;0.0182, n\u0026thinsp;=\u0026thinsp;8 of IT leaves extract). The results are shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e9\u003c/span\u003e.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec32\" class=\"Section2\"\u003e \u003ch2\u003e3.7 Influence on motor coordination\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eIT extract did not affect motor coordination in the Rotarod and chimney tests. Results are shown in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. Only one mouse from the group treated with IT extract at a dose of 100 mg/kg b.w. did not exit the chimney within 1 minute. However, we observed that in this group, the exit times were significantly longer compared to the control group (F(3,20)\u0026thinsp;=\u0026thinsp;2.697, p\u0026thinsp;=\u0026thinsp;0.0733, n\u0026thinsp;=\u0026thinsp;6). We assigned a time of 60 seconds to the mouse that did not come out of the chimney. Results are shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e10\u003c/span\u003e.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eThe effect of IT on motor coordination in the Rotarod and Chimney test in mice.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTreatment\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRotarod test\u003c/p\u003e \u003cp\u003e[% of animals that could not stay on a rotating rod for at least 1 minute]\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChimney test\u003c/p\u003e \u003cp\u003e[% of animals that did not climb out after 1 minute]\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1% Tween 80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIT 500 mg/kg\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIT 100 mg/kg\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16.67\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIT 50 mg/kg\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eIT \u0026ndash; \u003cem\u003eIsatis tinctoria\u003c/em\u003e extract. n\u0026thinsp;=\u0026thinsp;6 animals per group.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec33\" class=\"Section2\"\u003e \u003ch2\u003e3.8 Influence on hepatic enzyme activity in plasma\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eAfter administration of IT extract only a significant increase in alkaline phosphatase (AP) activity was determined in comparison to the plasma activity determined for the control group (F(3,28)\u0026thinsp;=\u0026thinsp;3.414, p\u0026thinsp;=\u0026thinsp;0.0310, n\u0026thinsp;=\u0026thinsp;8). The activity of the other enzymes determined in plasma of the treated group were comparable to the activity of these enzymes in the plasma of the control group. Results are shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e11\u003c/span\u003e.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec34\" class=\"Section2\"\u003e \u003ch2\u003e2.9 Influence on the total antioxidant activity of plasma\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe extract of IT leaves administered to mice at a dose of 500 mg/kg b.w. had a significant antioxidant effect one hour after intraperitoneal administration (F(3, 28)\u0026thinsp;=\u0026thinsp;7.116, p\u0026thinsp;=\u0026thinsp;0.0011, n\u0026thinsp;=\u0026thinsp;8). Results are shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig11\" class=\"InternalRef\"\u003e12\u003c/span\u003e.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"4. Discussion","content":"\u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eOur research demonstrates the anti-diabetic and neuroprotective potential of \u003cem\u003eIsatis tinctoria\u003c/em\u003e L. hydroalcoholic leaf extract for the first time. It shows that the effect of the extract on the reduction of protein glycation is significant. Additionally, IT extract inhibits alpha-glucosidase activity in a concentration dependent manner and AchE activity at some concentrations. We also show the results of preliminary \u003cem\u003ein vivo\u003c/em\u003e safety studies and show that intraperitoneal administration of hydroalcoholic extract of IT leaf at doses from 50 mg/kg b.w. to 500 mg/kg, is most likely safe for the organism. Moreover, the tested extract has no cytotoxic properties, even at concentrations characterized by a strong reducing effect.\u003c/p\u003e \u003cp\u003eNeurodegenerative, cardiovascular, and metabolic diseases have a significant negative effect on the quality of life and life span of the aging population. The increased accumulation of damaged proteins is responsible for the formation of bulky aggregates and plaques typical of the aforementioned diseases. Type 2 DM is one of the most important risk factors responsible for age-related cognitive impairment [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. The pathophysiology of AD is attributed to numerous factors such as cholinergic dysfunction, amyloid/tau toxicity and oxidative stress/mitochondrial dysfunction [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e]. Interestingly, clinical evidence considers hyperglycemia to be one of the risk factors for the development and progression of AD [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e]. Consequently, plant products that inhibit AchE activity, alpha-glucosidase activity, and protein glycation, in addition to exhibiting antioxidant properties, have anti-diabetic and neuroprotective potential.\u003c/p\u003e \u003cp\u003eNumerous medicinal herbs and dietary plants, containing polyphenols, were found to prevent protein glycation in \u003cem\u003ein vitro\u003c/em\u003e studies [\u003cspan additionalcitationids=\"CR36 CR37\" citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. The anti-glycating activity of many flavonoids, including quercetin, quercitrin, genistein, kaempferol, naringin, rutin, and propyl gallate, has been documented [\u003cspan additionalcitationids=\"CR40 CR41 CR42 CR43\" citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. Phenolic acids could effectively protect BSA from glycation \u003cem\u003ein vitro\u003c/em\u003e [\u003cspan additionalcitationids=\"CR46 CR47\" citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe IT extract we chose for our research contains many different compounds in various concentrations, including e.g.: vicenin-2 (7.51 mg/g), flavone-di-glucoside (6.42 mg/g), isovitexin (5.46 mg/g), stellarin-2 (4.69 mg/g), apigenin-di-glucoside (4.51 mg/g), apigenin-glucoside (4.68 mg/g), isoscoparin (3.89 mg/g), quercetin (1.86 mg/g), neochlorogenic acid (1.84 mg/g), sinapic acid (1.49 mg/g) and kaempferol (1.48 mg/g) [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. Some of these compounds have proven anti-glycation and antioxidant activity; and an inhibitory effect on some enzyme activity, e.g. alpha-glucosidase or AchE. Despite the inhibition of protein glycation by the extract being less intense than the inhibition exerted by the main compounds (vicenin-2 and quercetin) of this extract at the tested concentrations, it is still detectable.\u003c/p\u003e \u003cp\u003eEarlier studies clearly demonstrate that the accumulation of advanced glycation end products (AGEs) in tissue is the leading cause of age-related degeneration, atherosclerosis, and diabetic complications such as neuropathy, retinopathy, cardiomyopathy, and nephropathy [\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e, \u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e]. Recent studies suggest that AGEs interact with specific receptors (RAGE) in the plasma membrane, modifying gene expression, changing intracellular signal transmission, and promoting the release of free radicals and pro-inflammatory molecules [\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e, \u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e]. Therefore, inhibition of AGE formation is a potential therapeutic target for preventing the progression of the aforementioned complications of diabetes and protecting against the development of age-related cognitive impairment and neurodegenerative disorders.\u003c/p\u003e \u003cp\u003eAlpha-glucosidase is an enzyme located in the digestive tract which is responsible for breaking down carbohydrates to facilitate the absorption of monosaccharides. Inhibition of alpha-glucosidase activity can reduce diabetic complications [\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e, \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e], making its inhibition by the main compounds in IT, vicenin-2, quercetin, of great value [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. In our study, IT leaf extract was more active than these compounds at almost all the tested concentrations. The inhibition of alpha-glucosidase shows the potential of IT extract in the management of hyperglycemic states, diabetes, obesity, and neurodegenerative diseases.\u003c/p\u003e \u003cp\u003eAchE plays a key role in the hydrolysis of acetylcholine in the regulation of cholinergic neurotransmission [\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e]. Inhibitors of this enzyme can delay the progress of mental illness, thus providing a rational therapeutic alternative in the treatment of Alzheimer\u0026rsquo;s disease. Our study shows that IT extract has a weak inhibitory effect on AchE. Vicenin-2 and quercetin also possess weak activity in this regard. The effect on AchE activity can be considered as an additional benefit of this extract in the management of neurodegenerative disorders.\u003c/p\u003e \u003cp\u003eA limitation of our study is the difficulty in drawing a direct comparison between the potency of the extract and the potency of the main compounds. For that reason, we consider the results to be preliminary, since the main compounds isolated from IT and the reference compounds (acarbose, tacrine) were used in molar concentrations so that their activity could be compared, which cannot be done for the extract.\u003c/p\u003e \u003cp\u003eFew in vivo studies showing the effects of various IT leaf extracts on the organism are presented in the literature [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e, \u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e, \u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e], and these mainly concern their anti-inflammatory effect. Moreover, most of the manuscripts focus on the \u003cem\u003ein vitro\u003c/em\u003e activities of the various extracts of this plant with interesting therapeutic properties [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eOxidative stress is characteristic of many diseases including, type 2 diabetes mellitus, atherosclerosis, hypertension, chronic obstructive pulmonary disease, major depression, Alzheimer's disease, inflammation, and cancer, making the development of effective antioxidant therapies of great importance [\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e]. Free radicals are oxidizing agents, causing tissue damage. Uncontrolled oxidative activity is the basis of various pathological conditions and can be countered by antioxidant treatment. Nonetheless, oxidants may exert beneficial effects by regulating cell signaling cascades [\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e]. In an \u003cem\u003ein vitro\u003c/em\u003e study, we demonstrated the absence of cytotoxic activity by the tested extract on HT-22 cells, even at concentrations with significant reducing power. Subsequently, in plasma collected from animals, we determined the plasma reduction force by determining the reduction force of Fe3\u0026thinsp;+\u0026thinsp;ions, which is interpreted as the total antioxidant force of plasma [\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e]. IT extract administered to mice at a dose of 500 mg/kg b.w. had a significant antioxidant effect one hour after a single intraperitoneal administration. This is an important property of the extract \u003cem\u003ein vivo\u003c/em\u003e.\u003c/p\u003e \u003cp\u003eFrom the simple measurements of basal body weight after administration of the plant extract/compound, basic conclusions on the effects on the organism can be drawn. Since animals that feel somehow unwell after the administration of an agent have reduced locomotor activity [\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e, \u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e], and consume less food, they may lose significant body mass. Weight loss can also be the result of increased activity and calorie expenditure. It should be noted that such changes in the mice can be noticed in a short timeframe because they constantly consume food throughout the day [\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e]. Furthermore, it is worth noting that body weight is a dynamic parameter and that daily fluctuations, are within the range of approximately 2\u0026ndash;3% (in control animals).\u003c/p\u003e \u003cp\u003eIn our research, we measured body weight prior to and 24 hours after the administration of IT extract, weighed the amount of food consumed, and measured the influence on locomotor activity. The extract tested did not have a significant effect on mouse body weight. Interestingly, after administration of the extract at doses of 500 and 50 mg/kg b.w., a slight decrease in body weight was established. In all groups, the mice ate a similar amount of food within 24 h, that is, 20g/24h/6 mice\u0026thinsp;\u0026plusmn;\u0026thinsp;1 g. However, locomotor activity, after administration of the leaf extract at a dose of 50 mg/kg b.w., significantly decreased in comparison to the spontaneous activity determined in the control group. This observed decrease in activity could explain the slightly lower weight gain observed in this group after administration of the extract. A limitation of these studies is s the short time (5 minutes) allocated to determination of the effect of IT extract on spontaneous activity, therefore further studies should be carried out to monitor spontaneous activity for e.g., 24 hours after administration of the tested extracts. An interesting result is that IT extract only has a sedative effect at the lowest dose used. These differences in the effect on spontaneous activity may be attributed to the differences in the action of the compounds in the extract at different concentrations. At lower doses, certain compounds may have significant activity (sedation), whereas, at higher doses, other compounds may become active and suppress or counteract the effects of the compounds acting at lower doses.\u003c/p\u003e \u003cp\u003eIn our previous research, we demonstrated that IT hydroalcoholic leaf extract can reduce stress-induced behavioral disturbances by regulation of neuro-nitrosative, neuro-oxidative, and neuroimmune pathways [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. However, given the reports, some centrally acting compounds or drugs, e.g.: antidepressants, stress relievers, and anxiolytics, may negatively affect motor coordination [\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e, \u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e]. In view of this, we conducted preliminary safety studies to reduce the use of animals later on, since products that disturb motor coordination are excluded from further studies. The results obtained from the motor coordination tests clearly show that at the doses used, the IT extract does not significantly disturb the motor coordination of mice. However, it should be taken into account that at a dose of 100 mg/kg b.w., the extract significantly prolonged the time of exit of mice from the chimney compared to the time of exit from the chimney of the control mice - which suggests that at this dose, the activity of the compounds in the extract is the least safe. This coincides with the observations described in the earlier manuscript, where a dose of 100 mg/kg b.w. was considered the least favorable [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eAs part of the safety studies conducted, we also performed assays on plasma collected from animals to determine the activity of enzymes such as gamma-glutamyl transpeptidase (gGT), alkaline phosphatase (AP), alanine aminotransferase (AlaT), and aspartate aminotransferase (AspaT). These were done to check the acute effect of the tested extracts on liver cells (liver integrity or hepatocellular damage).\u003c/p\u003e \u003cp\u003eLiver toxicity is one of the most common difficulties encountered in drug development. However only 43% of the toxicities seen in rodents are observed humans, as was established by a retrospective study on the toxicity of pharmaceuticals in development [\u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e]. Enzymes synthesized in cells perform specific functions intracellularly, and few are secreted into the extracellular space. Each tissue has its own specific enzyme profile. The presence of intracellular enzymes in body fluids may indicate tissue damage (damage to the cell membrane \u0026ndash; reversible, or cell breakdown - irreversible). The current best-practice recommendation for nonclinical safety assessment is that a minimum of four serum parameters is used to assess hepatocellular (a minimum of two markers) and hepatobiliary (a minimum of two markers) injury [\u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e, \u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e]. Any two markers of glutamate dehydrogenase activity, sorbitol dehydrogenase activity, alanine transaminase activity, and aspartate transaminase activity, can be used to evaluate hepatocellular injury, whilst any two of gamma-glutamyl transferase activity, alkaline phosphatase activity, total bile acids and 5\u0026prime;-nucleotidase, total bilirubin can be used to assess hepatobiliary injury [\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn our study, we determined the activity of four enzymes in plasma 60 minutes after administration of the test extract, similarly as other authors earlier [\u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e]. After administration of the IT extract, only a significant increase in AP activity was determined in comparison to the activity determined for the control group. This difference was only observed at a dose of 100 mg/kg b.w. ip. Since plasma levels of AP increase as the patency of the bile duct is reduced, AP is widely used in nonclinical and human clinical settings as a marker of cholestatic liver injury [\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e]. In the absence of an increase in the other measured enzymes, especially gGT, hepatic disorders are excluded. It is known that fluctuations of AP need to be interpreted cautiously in nonclinical settings since there is an intestinal isoform of AP whose activity transiently increases postprandially [\u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e"},{"header":"5. Conclusions","content":"\u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe presented preliminary studies show that IT hydroalcoholic leaf extract exhibits antiglycation, anti-alpha-glucosidase, anti-AchE, antioxidant, anti-inflammatory properties and therefore also has anti-diabetic and neuroprotective potential. Additionally, \u003cem\u003ein vitro\u003c/em\u003e, and \u003cem\u003ein vivo\u003c/em\u003e safety studies in mice confirm that the tested extract does not cause coordination disorders and does not significantly affect body mass and liver enzyme activity. Depending on the dose used, it can have a sedative effect (which may be beneficial in some conditions). It has no cytotoxic effect on hippocampal cells, even at concentrations with significant reducing power. Therefore, hydroalcoholic extract of this plant may be considered for further research in the management of disorders linked to oxidative stress.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAuthor Contributions:\u003c/strong\u003e\u0026nbsp; \u0026nbsp;Conceptualization, and methodology, M.K.; formal analysis, M.K., N.N., M.B., M. G-L., R.H., P.Z., A.M., E.T.; investigation, M.K., N.N., M.B.; resources, I.K., N.M., S.R.; data curation, M.K.; writing - original draft preparation, M.K., N.N., M.B., M.G-L., I.K., K.M.; writing - review and editing, M.K., P.Z., N.N., A.A, I.K., N.M., E.R.L., J.S.; project administration, M.K.; visualization, M.K; funding acquisition, M.K., I.K.; supervision, M.K., I.K.; All authors have read and agreed to the published version of the manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInstitutional Review Board Statement:\u0026nbsp;\u003c/strong\u003eThe study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Local Ethics Committee for Experiments on Animals of the Jagiellonian University in Krakow (Permissions No: 473/2020, date: 16.12.2020; No: 545B/2021, date: 21.07.2021).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c/strong\u003e This work was supported by statutory funds (No N42/DBS/000285) from the Faculty of Pharmacy, Jagiellonian University, Medical College, Krakow, Poland.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgments:\u003c/strong\u003e Noemi Nicosia thanks the Prof. Antonio Imbesi Foundation for the fellowship.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePaula Zammit thanks the Erasmus+ Program for a scholarship at the Jagiellonian University.\u003c/p\u003e\n\u003cp\u003eHT-22 was a generous gift from Dr. Bartosz\u0026nbsp;Pomierny\u0026nbsp;of the Department of Biochemical Toxicology, Jagiellonian University Medical College, Krakow, Poland - the authors thank him very much for it.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflicts of Interest:\u003c/strong\u003e All authors declare that they have no conflicts of interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSample Availability:\u003c/strong\u003e The \u003cem\u003eIsatis tinctoria\u003c/em\u003e L. hydroalcoholic leaf extract was earlier characterized to full details of the chemical composition. The data have been presented in previous manuscripts (see\u0026nbsp;Miceli\u0026nbsp;et al., 2017[21], Taviano et al., 2018 [22]). Samples of the extract are available from the authors.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability statement:\u0026nbsp;\u003c/strong\u003eThe data that support the findings of this study are available from the corresponding author upon reasonable request.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eDilworth L, Facey A, Omoruy F (2021) Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues. Int J Mol Sci 2214:7644. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/ijms22147644\u003c/span\u003e\u003cspan address=\"10.3390/ijms22147644\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKashtoh H, Baek KH (2022) Recent Updates on Phytoconstituent Alpha-Glucosidase Inhibitors: An Approach towards the Treatment of Type Two Diabetes. Plants 1120:2722. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/plants11202722\u003c/span\u003e\u003cspan address=\"10.3390/plants11202722\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eThornalley PJ (2003) Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419(1):31\u0026ndash;40. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.abb.2003.08.013\u003c/span\u003e\u003cspan address=\"10.1016/j.abb.2003.08.013\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNeth BJ, Craft S (2017) Insulin Resistance and Alzheimer\u0026rsquo;s Disease: Bioenergetic Linkages. Front Aging Neurosci 9:345. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fnagi.2017.00345\u003c/span\u003e\u003cspan address=\"10.3389/fnagi.2017.00345\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJanoutov\u0026aacute; J, Machaczka O, Zatloukalov\u0026aacute; A, Janout V (2022) Is Alzheimer\u0026rsquo;s disease a type 3 diabetes? A review. Cent Eur J Public Health 30:139\u0026ndash;143. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.21101/cejph.a7238\u003c/span\u003e\u003cspan address=\"10.21101/cejph.a7238\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXu J, Lan Z, Wang S, Guo Y, Ning J, Song Y, Liu M, Tian C (2022) The pharmaceutical applications of total flavonoids extract from \u003cem\u003eIsatis tinctoria\u003c/em\u003e L. leaves. Pharm Research-Modern Chin Med 3:100122. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.prmcm.2022.100122\u003c/span\u003e\u003cspan address=\"10.1016/j.prmcm.2022.100122\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee SW, Cho YW (2019) Anti-Inflammatory Effect of the \u003cem\u003eIsatis tinctoria\u003c/em\u003e L. Root Extract on Lipopolysaccharide-Induced Periodontitis in Rats. J Bio Med 7:09: 81. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.4236/jbm.2019.79008\u003c/span\u003e\u003cspan address=\"10.4236/jbm.2019.79008\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKim EJ, Woo J, Shin S, Choi H, Kim Y, Kim J, Kang C (2022) A focused natural compound screen reveals senolytic and senostatic effects of Isatis tinctoria. Anim Cells Syst 310\u0026ndash;317. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1080/19768354.2022.2143895\u003c/span\u003e\u003cspan address=\"10.1080/19768354.2022.2143895\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEuropean Pharmacopeia 7th ed. Supple. 7.3 (2566); Isatis root (\u003cem\u003eIsaditis radix\u003c/em\u003e), 2011, European Directorate for the Quality of Medicines: Strasburg, Germany, pp. 3866\u0026ndash;3867\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEuropean Pharmacopeia, 11th ed.; Isatis root (Isaditis radix) (2022) European Directorate for the Quality of Medicines: Strasburg, Germany, pp. 1568\u0026ndash;1569\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen Q, Lan HY, Peng W, Rahman K, Liu QC, Luan X, Zhang H (2021) \u003cem\u003eIsatis indigotica\u003c/em\u003e: a review of phytochemistry, pharmacological activities and clinical applications. J Pharm Pharmacol 739:1137\u0026ndash;1150. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/jpp/rgab014\u003c/span\u003e\u003cspan address=\"10.1093/jpp/rgab014\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePharmacopoeia of the People\u0026rsquo;s Republic of China, 11th edition (2020) Chemical Industry Press, Beijing, China\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNie LX, Dong J, Huang LY, Qian XY, Lian CJ, Kang S, Dai Z, Ma SC (2021) Microscopic Mass Spectrometry Imaging Reveals the Distribution of Phytochemicals in the Dried Root of Isatis tinctoria. Front Pharmacol 12:685575. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fphar.2021.685575\u003c/span\u003e\u003cspan address=\"10.3389/fphar.2021.685575\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSperanza J, Miceli N, Taviano MF, Ragusa S, Kwiecień I, Szopa A, Ekiert H (2020) Isatis tinctoria L. (Woad): A review of its botany, ethnobotanical uses, phytochemistry, biological activities, and biotechnological studies. Plants 93:298. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/plants9030298\u003c/span\u003e\u003cspan address=\"10.3390/plants9030298\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRagusa M, Miceli N, Piras C, Bosco A, Castagna F, Rinaldi L, Musella V, Taviano FM, Britti D (2022) In Vitro Anthelmintic Activity of Isatis tinctoria Extracts against Ewes\u0026rsquo; Gastrointestinal Nematodes (GINs), a Possible Application for Animal Welfare. Vet Sci 93:129. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/vetsci9030129\u003c/span\u003e\u003cspan address=\"10.3390/vetsci9030129\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNguyen T, Marcelo P, Gontier E, Dauwe R (2019) Metabolic markers for the yield of lipophilic indole alkaloids in dried woad leaves (\u003cem\u003eIsatis tinctoria\u003c/em\u003e L). Phytochem 163:89\u0026ndash;98. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.phytochem.2019.04.006\u003c/span\u003e\u003cspan address=\"10.1016/j.phytochem.2019.04.006\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSteriti RND (2002) Nutritional support for chronic myelogenous and other leukaemias: a review of the scientific literature. Altern Med Rev 75:404\u0026ndash;409\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEisenbrand G, Hippe F, Jakobs S, Muehlbeyer S (2004) Molecular mechanisms of indirubin and its derivatives: Novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol 130:627\u0026ndash;635. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00432-004-0579-2\u003c/span\u003e\u003cspan address=\"10.1007/s00432-004-0579-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRecio MC, Cerd\u0026aacute;-Nicol\u0026aacute;s M, Potterat O, Hamburger M, R\u0026iacute;os JL (2006) Anti-Inflammatory and Antiallergic Activity in vivo of Lipophilic Isatis tinctoria Extracts and Tryptanthrin. Planta Med 7206:539\u0026ndash;546. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1055/s-2006-931562\u003c/span\u003e\u003cspan address=\"10.1055/s-2006-931562\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRecio MC, Cerd\u0026aacute;-Nicol\u0026aacute;s M, Hamburger M, Rios LJ (2006) Anti-arthritic activity of a lipophilic woad (\u003cem\u003eIsatis tinctoria\u003c/em\u003e) extract. Planta Med 72 08:715\u0026ndash;720. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1055/s-2006-941507\u003c/span\u003e\u003cspan address=\"10.1055/s-2006-941507\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMiceli N, Filocamo A, Ragusa S, Cacciola F (2017) Chemical Characterization and Biological Activities of Phenolic-Rich Fraction from Cauline Leaves of \u003cem\u003eIsatis tinctoria\u003c/em\u003e L. (Brassicaceae) Growing in Sicily, Italy. Chem Bio 14:8: e1700073. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/cbdv.201700073\u003c/span\u003e\u003cspan address=\"10.1002/cbdv.201700073\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTaviano MF, Filocamo A, Ragusa S, Cacciola F, Dugo P, Modello L, Mastrazzo PG, De Rose RF, Celano M, Lombardo GE, Melchini A, Miceli N (2018) Phenolic profile, antioxidant and cytotoxic properties of polar extracts from leaves and flowers of \u003cem\u003eIsatis tinctoria\u003c/em\u003e L. (Brassicaceae) growing in Sicily. Plant Biosyst 1524:795\u0026ndash;803. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1080/11263504.2017.1338629\u003c/span\u003e\u003cspan address=\"10.1080/11263504.2017.1338629\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAdawara SN, Shallangwa GA, Mamza P, Ibrahim A (2020) Anti-dengue potential, molecular docking study of some chemical constituents in the leaves of \u003cem\u003eIsatis tinctoria\u003c/em\u003e. Chem Rev Lett 33:104\u0026ndash;109. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.22034/CRL.2020.228931.1054\u003c/span\u003e\u003cspan address=\"10.22034/CRL.2020.228931.1054\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNicosia N, Kwiecień I, Mazurek J, Mika K, Bednarski M, Miceli N, Ragusa S, Ekiert H, Maes M, Kotańska M (2022) Hydroalcoholic Leaf Extract of \u003cem\u003eIsatis tinctoria\u003c/em\u003e L. via Antioxidative and Anti-Inflammatory Effects Reduces Stress-Induced Behavioral and Cellular Disorders in Mice. Oxid Med Cell Longev 2022:3567879. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1155/2022/3567879\u003c/span\u003e\u003cspan address=\"10.1155/2022/3567879\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIslam MN, Ishita IJ, Jung HA, Choi JS (2014) Vicenin 2 isolated from \u003cem\u003eArtemisia capillaris\u003c/em\u003e exhibited potent anti-glycation properties. Food Chem Toxicol 69:55\u0026ndash;62. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.fct.2014.03.042\u003c/span\u003e\u003cspan address=\"10.1016/j.fct.2014.03.042\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMarrassini C, Davicino R, Acevedo C, Anesini C, Gorzalczany S, Ferraro G (2011) Vicenin-2, a potential anti-inflammatory constituent of \u003cem\u003eUrtica circularis\u003c/em\u003e. J Nat Prod 746:1503\u0026ndash;1507. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/np100937e\u003c/span\u003e\u003cspan address=\"10.1021/np100937e\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlsadat AM, Nikbakht F, Nia HH, Golab F, Khadem Y, Barati M, Vazifekhah S (2021) GSK-3β as a target for apigenin-induced neuroprotection against Aβ 25\u0026ndash;35 in a rat model of Alzheimer's disease. Neuropeptides 90:102200. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.npep.2021.102200\u003c/span\u003e\u003cspan address=\"10.1016/j.npep.2021.102200\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHamburger M (2002) \u003cem\u003eIsatis tinctoria\u003c/em\u003e - From the rediscovery of an ancient medicinal plant towards a novel anti-inflammatory phytopharmaceutical. Phytochem Rev 1:333\u0026ndash;344\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChoi JS, Islam MN, Ali MY, Kim EJ, Kim YM, Jung HA (2013) Effect of C-glycosylation on anti-diabetic, anti-Alzheimer\u0026rsquo;s disease, and anti-inflammatory potential of apigenin. Food Chem Tox 64:27\u0026ndash;33. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.fct.2013.11.020\u003c/span\u003e\u003cspan address=\"10.1016/j.fct.2013.11.020\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhou Y, Jiang Q, Ma S, Zhou X (2021) Effect of quercetin on the in vitro Tartary buckwheat starch digestibility. Int J Biol Macromol 183:818\u0026ndash;830. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ijbiomac.2021.05.013\u003c/span\u003e\u003cspan address=\"10.1016/j.ijbiomac.2021.05.013\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi YQ, Zhou FC, Gao F, Bian JS, Shan F (2009) Comparative evaluation of quercetin, isoquercetin and rutin as inhibitors of alpha-glucosidase. J Agric Food Chem 5724:11463\u0026ndash;11468. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/jf903083h\u003c/span\u003e\u003cspan address=\"10.1021/jf903083h\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSadowska-Bartosz I, Bartosz G (2016) Effect of glycation inhibitors on aging and age-related diseases. Mech Ageing Dev 160:1\u0026ndash;18. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.mad.2016.09.006\u003c/span\u003e\u003cspan address=\"10.1016/j.mad.2016.09.006\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMohamed T, Shakeri A, Rao PP (2016) Amyloid cascade in Alzheimer's disease: Recent advances in medicinal chemistry. Eur J Med Chem 113:258\u0026ndash;272. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ejmech.2016.02.049\u003c/span\u003e\u003cspan address=\"10.1016/j.ejmech.2016.02.049\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCraft S, Dagogo-Jack SE, Wiethop BV, Murphy C, Nevins RT, Fleischman S, Rice V, Newcomer JW, Cryer PE (1993) Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci 107:926\u0026ndash;940. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1037/0735-7044.107.6.926\u003c/span\u003e\u003cspan address=\"10.1037/0735-7044.107.6.926\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAhmad H, Khan I, Wahid A (2012) Antiglycation and antioxidation properties of Juglans regia and Calendula officinalis: Possible role in reducing diabetic complications and slowing down ageing. J Tradit Chin Med 32:411\u0026ndash;414. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S0254-6272(13)60047-3\u003c/span\u003e\u003cspan address=\"10.1016/S0254-6272(13)60047-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJang DS, Yoo NH, Kim NH, Lee YM, Kim CS, Kim J, Kim JH, Kim JS (2010) 3,5-Di-O-caffeoyl-epi-quinic acid from the leaves and stems of Erigeron annuus inhibits protein glycation, aldose reductase, and cataractogenesis. Biol Pharm Bull 33:329\u0026ndash;333. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1248/bpb.33.329\u003c/span\u003e\u003cspan address=\"10.1248/bpb.33.329\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHarris CS, Cuerrier A, Lamont E, Haddad PS, Arnason JT, Bennett SA, Johns T (2014) Investigating wild berries as a dietary approach to reducing the formation of advanced glycation endproducts: Chemical correlates of in vitro antiglycation activity. Plant Foods Hum Nutr 6:71\u0026ndash;77. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11130-014-0403-3\u003c/span\u003e\u003cspan address=\"10.1007/s11130-014-0403-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRamkissoon JS, Mahomoodally MF, Ahmed N, Subratty AH (2013) Antioxidant and anti-glycation activities correlate with phenolic composition of tropical medicinal herbs. Asian Pac J Trop Med 6:561\u0026ndash;569. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S1995-7645(13)60097-8\u003c/span\u003e\u003cspan address=\"10.1016/S1995-7645(13)60097-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLv L, Shao X, Chen H, Ho CT, Sang S (2011) Genistein inhibits advanced glycation product formation by trapping methylglyoxal. Chem Res Toxicol 24:579\u0026ndash;586. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S1995-7645(13)60097-8\u003c/span\u003e\u003cspan address=\"10.1016/S1995-7645(13)60097-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBournival J, Francoeur MA, Renaud J, Martinoli MG (2012) Quercetin and sesamin protect neuronal PC12 cells from high-glucose-induced oxidation; nitrosative stress; and apoptosis. Rejuvenation Res 15:322\u0026ndash;333. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1089/rej.2011.1242\u003c/span\u003e\u003cspan address=\"10.1089/rej.2011.1242\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSadowska-Bartosz I, Galiniak S, Bartosz G (2014a) Kinetics of glycoxidation of bovine serum albumin by methylglyoxal and glyoxal and its prevention by various compounds. Molecules 19:4880\u0026ndash;4896. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/molecules19044880\u003c/span\u003e\u003cspan address=\"10.3390/molecules19044880\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSadowska-Bartosz I, Galiniak S, Bartosz G (2014b) Kinetics of glycoxidation of bovine serum albumin by glucose, fructose and ribose and its prevention by food components. Molecules 19:18828\u0026ndash;18849. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/molecules191118828\u003c/span\u003e\u003cspan address=\"10.3390/molecules191118828\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXie Y, Chen X (2013) Structures required of polyphenols for inhibiting advanced glycation end products formation. Curr Drug Metab 14:414\u0026ndash;431. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2174/1389200211314040005\u003c/span\u003e\u003cspan address=\"10.2174/1389200211314040005\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSasaki K, Chiba S, Yoshizaki F (2014) Effect of natural flavonoids: Stilbenes and caffeic acid oligomers on protein glycation. Biomed Rep 2:628\u0026ndash;632. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3892/br.2014.304\u003c/span\u003e\u003cspan address=\"10.3892/br.2014.304\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAdisakwattana S, Sompong W, Meeprom A, Ngamukote S, Yibchok-Anun S (2012) Cinnamic acid and its derivatives inhibit fructose-mediated protein glycation. Int J Mol Sci 13:1778\u0026ndash;1789. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/ijms13021778\u003c/span\u003e\u003cspan address=\"10.3390/ijms13021778\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSilv\u0026aacute;n JM, Assar SH, Srey C, Del Castillo MD, Ames JM (2011) Control of the Maillard reaction by ferulic acid. Food Chem 128:208\u0026ndash;213. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.foodchem.2011.03.047\u003c/span\u003e\u003cspan address=\"10.1016/j.foodchem.2011.03.047\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSompong W, Meeprom A, Cheng H, Adisakwattana S (2013) A comparative study of ferulic acid on different monosaccharide-mediated protein glycation and oxidative and oxidative damage in bovine serum albumin. Molecules 18:13886\u0026ndash;13903. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/molecules181113886\u003c/span\u003e\u003cspan address=\"10.3390/molecules181113886\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMeeprom A, Sompong W, Chan CB, Adisakwattana S (2013) Isoferulic acid, a new anti-glycation agent, inhibits fructose- and glucose-mediated protein glycation in vitro. Molecules 18:6439\u0026ndash;6454. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/molecules18066439\u003c/span\u003e\u003cspan address=\"10.3390/molecules18066439\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchmidt AM, Bakhti M (2000) Alherosclerosis and diabetes: The RAGE connection. Curr Atheroscler Rep 2:430\u0026ndash;436. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11883-000-0082-4\u003c/span\u003e\u003cspan address=\"10.1007/s11883-000-0082-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBrownlee M (1995) Advanced protein glycosylation in diabetes and aging. Annu Rev Med 146:223\u0026ndash;234. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1146/annurev.med.46.1.223\u003c/span\u003e\u003cspan address=\"10.1146/annurev.med.46.1.223\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShen CY, Lu CH, Wu CH, Le KJ, Kuo YM, Hsieh SC, Yu CL (2020) The development of Maillard reaction, and advanced glycation end product (AGE)-receptor for AGs (RAGE) signaling inhibitors as novel therapeutic strategies for patients with age-related diseases. Molecules 25:5591. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/molecules25235591\u003c/span\u003e\u003cspan address=\"10.3390/molecules25235591\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChukwuma CI, Islam S (2015) Effects of xylitol on carbohydrate digesting enzymes activity, intestinal glucose absorption and muscle glucose uptake: a multi-mode study. Food Funct 6:955. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1039/c4fo00994k\u003c/span\u003e\u003cspan address=\"10.1039/c4fo00994k\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBojarova P, Kren V (2009) Glicosidases: a key to tailored carbohydrates. Trends Biotechnol 27:199\u0026ndash;209. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.tibtech.2008.12.003\u003c/span\u003e\u003cspan address=\"10.1016/j.tibtech.2008.12.003\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAsano N (2003) Glycosidase inhibitors: update and perspectives on practical use. Glycobiology 13:93\u0026ndash;104. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/glycob/cwg090\u003c/span\u003e\u003cspan address=\"10.1093/glycob/cwg090\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSilman I, Sussman JL (2008) Acetylcholinesterase: how is structurerelated to function? Chem Biol Interact 175:3\u0026ndash;10. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.cbi.2008.05.035\u003c/span\u003e\u003cspan address=\"10.1016/j.cbi.2008.05.035\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBrattstr\u0026ouml;m A, Schapowal A, Kamal MA, Maillet I (2010) The plant extract \u003cem\u003eIsatis tinctoria\u003c/em\u003e L. extract (ITE) inhibits allergen-induced airway inflammation and hyperreactivity in mice. Phytomedicine 17:551\u0026ndash;556. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.phymed.2009.11.003\u003c/span\u003e\u003cspan address=\"10.1016/j.phymed.2009.11.003\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJiang L, Lu Y, Jin J, Dong L, Xu F, Chen S, Wang Z, Liang G, Shan X (2015) n-Butanol extract from Folium isatidis inhibits lipopolysaccharide-induced inflammatory cytokine production in macrophages and protects mice against lipopolysaccharide-induced endotoxic shock. Drug Des Devel Ther 9:5601\u0026ndash;5609. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2147/DDDT.S89924\u003c/span\u003e\u003cspan address=\"10.2147/DDDT.S89924\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDanz H, Stoyanova S, Wippich P, Brattstr\u0026ouml;m A, Hamburger M (2001) Identification and isolation of the cyclooxygenase-2 inhibitory principle in \u003cem\u003eIsatis tinctoria\u003c/em\u003e. Planta Med 67:411\u0026ndash;416. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1055/s-2001-15805\u003c/span\u003e\u003cspan address=\"10.1055/s-2001-15805\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eForman HJ, Zhang H (2021) Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug Discov 20:689\u0026ndash;709. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41573-021-00233-1\u003c/span\u003e\u003cspan address=\"10.1038/s41573-021-00233-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDi Meo S, Venditti P, Reed TT, Victor MV (2018) Harmful and Beneficial Role of ROS 2017. Oxid Med Cell Longev 2018:5943635. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1155/2018/5943635\u003c/span\u003e\u003cspan address=\"10.1155/2018/5943635\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBenzie I, Strain J (1999) Direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic. Enzymology 299:15\u0026ndash;27. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s0076-6879(99)99005-5\u003c/span\u003e\u003cspan address=\"10.1016/s0076-6879(99)99005-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eReiter LW, MacPhail RC (1979) Motor activity: a survey of methods with potential use in toxicity testing. Neurobehav Toxicol 1:53\u0026ndash;66\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLynch JJ, Castagn\u0026eacute; V, Moser PC, Mittelstadt WS (2011) Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies. J Pharma Tox Meth 64:74\u0026ndash;80. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.vascn.2011.03.003\u003c/span\u003e\u003cspan address=\"10.1016/j.vascn.2011.03.003\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClaassen V (1994) Neglected factors in pharmacology and neuroscience research. Food and water intake. In: Hudson JP (ed) Techniques in the Behavioral and Neural Sciences, vol 12. Elsevier, Amsterdam, pp 267\u0026ndash;287. Chap. 12\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStr\u0026ouml;mberg C (1988) Interactions of antidepressants and ethanol on spontaneous locomotor activity and rotarod performance in NMRI and C57BL/6 mice. J Psychopharmacol 2:61\u0026ndash;66. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1177/026988118800200201\u003c/span\u003e\u003cspan address=\"10.1177/026988118800200201\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSzkutnik-Fiedler D, Kus K, Balcerkiewicz M, Grześkowiak E, Nowakowska E, Burda K, Ratajczak P, Sadowski C (2012) Concomitant use of tramadol and venlafaxine: Evaluation of antidepressant- like activity and other behavioral effects in rats. Pharmacol Rep 64:1350\u0026ndash;1358. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s1734-1140(12)70932-5\u003c/span\u003e\u003cspan address=\"10.1016/s1734-1140(12)70932-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOlson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Duen K, Smith P, Berger B, Heller A (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56\u0026ndash;67\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBoone L, Meyer D, Cusick P, Ennulat D, Bolliger A, Everds N, Meador V, Elliott G, Honor D, Bounous D, Jordan H (2005) Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet Clin Path 34:182\u0026ndash;188. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/j.1939-165x.2005.tb00041.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1939-165x.2005.tb00041.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVuppalanchi R, Chalasani N (2018) Laboratory Tests in Liver Disease. In: Saxena R (ed) Practical Hepatic Pathology: A Diagnostic Approach. Elsevier, Philadelphia, PA, USA, pp 43\u0026ndash;53\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAulbach A, Amuzie CJ (2017) Biomarkers in Nonclinical Drug Development. In: A Comprehensive guide to toxicology in nonclinical drug development. Academic Press, pp 447\u0026ndash;471\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJarsiah P, Nosrati A, Alizadeh A, Hashemi-Soteh S (2017) Hepatotoxicity and ALT/AST Enzymes Activities Change in Therapeutic and Toxic Doses Consumption of Acetaminophen in Rats. Int Biol Biomed J 3:119\u0026ndash;124\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVinson JA, Howard TBIII (1996) Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. J Nutr Biochem 7:659\u0026ndash;663. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S0955-2863(96)00128-3\u003c/span\u003e\u003cspan address=\"10.1016/S0955-2863(96)00128-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKotańska M, Szafarz M, Mika K, Dziubina A, Bednarski M, Muller C, Sapa J, Kieć-Konowicz K (2021) PSB 603 \u0026ndash; a known selective adenosine A2B receptor antagonist\u0026ndash;has anti-inflammatory activity in mice. Biomed Pharmacother 135:111164. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.biopha.2020.111164\u003c/span\u003e\u003cspan address=\"10.1016/j.biopha.2020.111164\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKuder KJ, Kotańska M, Szczepańska K, Mika K, Reiner-Link D, Stark H, Kieć-Konowicz K (2021) Discovery of Potential, Dual-Active Histamine H3 Receptor Ligands with Combined Antioxidant Properties. Molecules 26:2300. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/molecules26082300\u003c/span\u003e\u003cspan address=\"10.3390/molecules26082300\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ehttps://\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003etools.thermofisher.com/content/sfs/manuals/PrestoBlue_Reagent_PIS_15Oct10.pdf\u003c/span\u003e\u003cspan address=\"http://tools.thermofisher.com/content/sfs/manuals/PrestoBlue_Reagent_PIS_15Oct10.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ehttps://\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ebioscience.lonza.com/lonza_bs/CH/en/download/product/asset/28213\u003c/span\u003e\u003cspan address=\"http://bioscience.lonza.com/lonza_bs/CH/en/download/product/asset/28213\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBoissier PJ-R, Tardy J, Diverres J-C (1960) A new simple method to explore the tranquillizing action: the chimney test. Med Exp 3:81\u0026ndash;84\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKubacka M, Mogilski S, Bednarski M, Nowiński L, Dudek M, Żmudzka E, Siwek A, Waszkielewicz MA, Marona H, Satała G, Bojarski A, Filipek B, Pytka K (2016) Antidepressant-like activity of aroxyalkyl derivatives of 2-methoxyphenyl piperazine and evidence for the involvement of serotonin receptor subtypes in their mechanism of action. Pharmacol Biochem Behav 141:28\u0026ndash;41. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.pbb.2015.11.013\u003c/span\u003e\u003cspan address=\"10.1016/j.pbb.2015.11.013\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJastrzębska-Więsek M, Kotańska M, Grzeszczak A, Jaromin A, Walczak M, Partyka A, Gdula-Argasińska J, Smolik M, Zag\u0026oacute;rska A (2022) The Antidepressant-like Activity, Effects on Recognition Memory Deficits, Bioavailability, and Safety after Chronic Administration of New Dual-Acting Small Compounds Targeting Neuropsychiatric Symptoms in Dementia. Int J Mol Sci 23:11452. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/ijms231911452\u003c/span\u003e\u003cspan address=\"10.3390/ijms231911452\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Isatis tinctoria L, vicenin-2, anti-diabetic, neuroprotection, cytotoxicity, safety","lastPublishedDoi":"10.21203/rs.3.rs-4208153/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4208153/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eObjectives\u003c/h2\u003e \u003cp\u003eNatural plant raw materials, previously underestimated in therapeutics, are becoming the subject of research for new applications in medicine. In our research, the hydroalcoholic extract of \u003cem\u003eIsatis tinctoria\u003c/em\u003e leaf, rich in flavonoid compounds such as vicenin-2 and quercetin, was examined as a potential antidiabetic and neuroprotective agent.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eThe effect of the extract and its main flavonoid compounds on protein glycation, alpha-glucosidase activity, and acetylcholinesterase activity was tested. \u003cem\u003eIn vitro\u003c/em\u003e, in the mouse hippocampal neuronal cell line and \u003cem\u003ein vivo\u003c/em\u003e, using a mouse model, the safety of the extract was screened for.\u003c/p\u003e\u003ch2\u003eKey findings:\u003c/h2\u003e \u003cp\u003eOur experiments demonstrated significant inhibition of protein glycation, alpha-glucosidase activity, and acetylcholinesterase activity by the extract, in a concentration dependent manner. The extract had a strong reducing effect, did not exhibit cytotoxicity up to a concentration of 25 mg/mL. Intraperitoneal administration of the extract to mice did not have negative effects on body mass, locomotor activity, coordination, and liver cell integrity.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e \u003cp\u003eOur research sheds a new light on this raw material and deepens knowledge of its activity. This may result in the recognition of its therapeutic effects and even in its introduction in the modern treatment of diseases characterized by pathological changes associated with hyperglycemia, oxidation, and inflammation.\u003c/p\u003e","manuscriptTitle":"Anti-diabetes and neuroprotection potential and primary safety studies of Isatis tinctoria L. hydroalcoholic leaf extract","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-04-10 18:40:32","doi":"10.21203/rs.3.rs-4208153/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"5cd71617-4927-43cf-956e-e7ea0fd8c642","owner":[],"postedDate":"April 10th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2024-07-26T12:33:14+00:00","versionOfRecord":{"articleIdentity":"rs-4208153","link":"https://doi.org/10.1016/j.fitote.2024.106138","journal":{"identity":"fitoterapia","isVorOnly":true,"title":"Fitoterapia"},"publishedOn":"2024-07-01 12:33:13","publishedOnDateReadable":"July 1st, 2024"},"versionCreatedAt":"2024-04-10 18:40:32","video":"","vorDoi":"10.1016/j.fitote.2024.106138","vorDoiUrl":"https://doi.org/10.1016/j.fitote.2024.106138","workflowStages":[]},"version":"v1","identity":"rs-4208153","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4208153","identity":"rs-4208153","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}